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ABSTRACT 
A ROLE FOR SOX9 AND WNT-RELATED PROTEINS IN ENDOMETRIAL 
ADENOCARCINOMA 
H. Draper 
Introduction: Endometrial carcinoma is already the most common gynaecological 
malignancy in the developed world, and by 2015 the incidence is set to be twice that of 
2005. Despite this, therapeutic options available for advanced disease are very limited. 
The canonical Wnt/β-catenin pathway is known to have a key role in homeostasis of 
normal endometrial cellular proliferation and differentiation, and is also implicated in 
endometrial proliferative conditions such as carcinogenesis. SOX9 is a postulated Wnt-
regulator and may play a key role in establishment and maintenance of characteristic 
phenotypes of glandular cells during the menstrual cycle. The interaction of Wnt/β-
catenin pathway and SOX9 in the endometrium is not known, neither are the effects of 
ovarian steroids on these pathways and proteins fully elucidated.  The expression of a 
panel of Wnt-related proteins in endometrial cancer tissue samples was compared to 
normal pre- and post-menopausal endometrium.  Further in vitro work investigated 
the effect of ovarian steroid hormones on SOX9 and steroid receptor expression in a 
well characterised, well differentiated endometrial carcinoma cell line Ishikawa.  
Methods: 51 primary endometrial samples (31 endometrial adenocarcinomas (EC), 10 
normal proliferative phase (PP) and 10 normal post-menopausal (PM)) were assessed 
for the expression of SOX9, Ki67, β-catenin, SOX2, SFRS2, and NAP1L1 using 
immunohistochemistry. The Ishikawa cell line was maintained in phenol-free charcoal 
stripped media for 72 hours, and then treated with ovarian steroids: estradiol (E2), 
medroxyprogesterone acetate (MPA), E2 + MPA, basic fibroblast growth factor (FGF), 
and 5-alpha-dihydrotestosterone (DHT) for 72 hours. RT-PCR was performed for 
oestrogen receptor α (ER), progesterone receptor (PR), and SOX9. Statistical analysis 
used the Mann-Whitney and Spearman Rank tests. 
Results: Nuclear β-catenin was correlated with the Wnt-related proteins SOX2 
(p=0.025), NAP1L1 (p=0.046) and SFRS2 (p=0.032). However, none of these proteins 
demonstrated significantly different expression across the groups. The expression of 
SOX9 was significantly lower in the proliferative tissues (PP and EC) than the atrophic 
PM (p<0.0001). Correspondingly Ki67 was significantly lower in the PM samples than 
the PP and EC (p<0.0001). SOX9 and Ki67 also demonstrated an inverse relationship 
(p=0.032). ER expression was not altered by any of the ovarian steroid hormones. PR 
was up-regulated by E2 (1.8 fold, p=0.036), E2+MPA (1.5 fold, p=0.071) and DHT (1.9 
fold, p=0.036) from baseline. SOX9 was down-regulated 1.5-fold by both MPA 
(p=0.036), FGF (p=0.036) and DHT (not statistically significant).  
Discussion: These results provide further evidence for the pivotal role played by Wnt 
in the normal and malignant endometrium.  This also forms the first report identifying 
the Wnt-related proteins NAP1L1 and SFRS2 in the malignant endometrium. SOX9 is 
differentially expressed between proliferative and atrophic endometria, and can be 
down-regulated by MPA, FGF and DHT.  This therefore provides preliminary data on a 
role for androgens in the endometrium, since DHT was demonstrated to alter 
expression of both PR and SOX9.  Androgens are the dominant hormone in the post-
menopausal endometrium, from which endometrial cancer almost exclusively arises; 
further work expanding our understanding of androgens is therefore vital.  Novel 
treatment strategies manipulating the Wnt pathway using androgens can be envisaged 
to treat this common cancer in the future. 
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Chapter 1. Introduction 
 
 
The endometrium is arguably the most plastic of the adult human organs.  
Unfortunately, the mechanisms which lend it this remarkable ability to regenerate 
are also implicated in the endometrial proliferative conditions.  Endometrial 
adenocarcinoma is the most common gynaecological malignancy, and whilst its 
incidence rises at a startling rate, survival rates are static, resulting in a rising death 
toll.  In addition to regulating the fine balance between differentiation and 
proliferation in the normal cycling endometrium, the canonical Wnt/β-catenin 
pathway is increasingly thought to be a key factor in endometrial carcinogenesis.  A 
thorough review of the currently available literature was conducted of the structure 
and function of the endometrium, endometrial adenocarcinoma and Wnt-related 
protein in the endometrium.    
 
1.1. The human uterus and endometrium 
1.1.1 Anatomy  
 
The human uterus lies at the centre of the female reproductive tract; it is a highly 
muscular, hollow, pear shaped organ measuring approximately 8 x 5 x 3 cms8 (Figure 
1).  Its primary function is the vital role of enabling the development of the embryo to 
fetus following migration of the ovum from the ovaries to the uterus via the fallopian 
tubes.  It also serves as a conduit for migrating sperm2.  The uterus comprises of a 
fundus, body and cervix.  The fallopian tubes protrude superiorly from the uterus, 
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and inferiorly the cervix opens into the vaginal vault via the external os9.  The uterus 
lies in the pelvic cavity, approximately in the midline, with close relations to both the 
urinary bladder and rectum8.  Embryologically, the female reproductive tract is 
derived from mesoderm; the two Müllerian (paramesonephric) ducts differentiate 
into oviducts, uterus, cervix and upper portion of the vagina3. 
 
 
 
 
 
 
 
 
 
 
 
 
The blood supply for the uterus, and therefore the endometrium is provided by the 
arcuate arteries which arise from the uterine and ovarian arteries9.  The radial 
arteries arise from these in the myometrium.  Crossing from the myometrium to the 
endometrium, they branch to form the basal and spiral arteries which are 
anastomosing and terminal arteries respectively.  The functional layer is supplied by 
the branching spiral arteries which form a sub-epithelial plexus just below the 
surface, draining into venous sinuses10. 
Figure 1: Anatomy of the female reproductive tract.  Adapted from Drake et al..
2 
3 
 
The vasculature within the endometrium must undergo cycles of growth and 
regression due to the menstrual cycle, which makes it unique in the human body.  
During the proliferative phase, the growth of the functionalis is accompanied by 
similar growth in the vascular tree.  By the end of this phase, the terminal branches 
have become coiled, and these spiral arteries ascend from the basal to the functional 
layer during the secretory phase10. 
 
Structurally the uterus is composed of two layers; the thick muscular fibro-elastic 
myometrium8, and the inner endometrium which is arguably the most plastic organ 
within the human body.  In preparation for implantation of a fertilised blastocyst, the 
endometrium must be fully re-organised monthly following menstruation.  This 
occurs under the influence of cyclical variations in sex steroid hormones, the 
mechanism of which involves a wide variety of local autocrine and paracrine actions 
including enzymes, hormones and bioactive peptides10.  The precise mechanisms of 
some of these actions are far from being fully defined. 
 
1.1.2 Endometrium 
 
The endometrium of the uterine corpus is composed of a lower basal layer (stratum 
basalis) adjacent to the myometrium, and the superficial functional layer (stratum 
functionalis)3.  The functionalis regenerates monthly to accommodate the blastocyst 
should fertilisation occur, and subsequently provide the maternal portion of the 
placenta during pregnancy3.  The basalis is the putative location of the endometrial 
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stem or progenitor cell11, and is necessary for the cyclical regeneration of the 
functionalis. 
 
In addition to their differing function, there are histological differences between the 
functionalis and basalis layers.  The functionalis comprises the outer two thirds and 
can be further divided into the most superficial layer consisting of few simple 
epithelial tubular glands in an abundant vascularised stroma (zona compacta), and 
the deeper zona spongiosa which has more glands but relatively sparse stroma10.  
The basalis consists of dense stroma, large blood vessels and glandular bases10. 
 
The endometrial epithelial glands are crucial to the normal physiology of the 
endometrium.  The luminal epithelium is comprised of a single layer of columnar 
epithelium which invaginates into the underlying stroma to form the endometrial 
epithelial glands.  The glands descend from the luminal epithelium through both the 
functionalis and basalis layers and to meet the myometrium12.  In vitro recombinant 
tissue studies using mouse models demonstrated that the adult endometrial 
epithelium has the ability to grow in non-uterine stroma whilst maintaining its gene 
expression pattern13.  In addition, the epithelial glands are the location of origin of 
the endometrial proliferative conditions.  Proliferative conditions affecting the 
stroma, such as uterine stromal sarcomas, are very rare14. 
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1.1.3 Stroma  
 
 
The connective tissue surrounding the endometrial glands is known as the stroma.    
It has a vital role in the functioning of the endometrium, and there is much cross-talk 
between the glands and the stroma15.  In addition to the complex extra-cellular 
matrix, it is composed of a variety of cell types.  The primary cell-type is the stromal 
or reticular cell; a fibroblast-like cell which produces the extracellular matrix10.  Other 
cell types present include natural killer cells and lymphocytes16.  For all these cells, 
their morphology and density changes with both location in the endometrium and 
phase of the cycle.  For example, lymphocytes represent just 7% of stromal cells 
during the proliferative cells, rising to 30% during early pregnancy16.  The 
immunological complexities of implantation and pregnancy require a wide range of 
immuno-competent cells including T lymphocytes, macrophages and endometrial 
granulated lymphocytes10.  Disruption in the numbers of the immune cells has been 
reported in various conditions including unexplained infertility supporting their role 
in the appropriate functioning of the endometrium16. 
 
1.1.4 Menstrual cycle 
 
 
The menstrual cycle can be broadly divided into three phases (Figure 2); the 
proliferative phase (days 5-14), the secretory phase (days 14-28), and menstruation 
(days 1-4).  The proliferative phase follows menstruation, during which in the 
absence of implantation, the functional layer of the endometrium is shed.  This is 
triggered by a fall in both oestrogen and progesterone due to the destruction of the 
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corpus luteum.  The effect of other ovarian steroid hormones with cyclical changes 
such as androgens on endometrium is not yet fully understood.  The proliferative 
phase is marked by the regeneration of both the stromal and epithelial 
compartments of the functionalis.  Some 3-4mm of endometrium grows during this 
phase under the influence of oestrogen.  Once the endometrium is restored to its full 
thickness, the glands undergo significant changed in structure and secrete a 
glycogen-rich material ready to make the endometrium receptive to the blastocyst; 
these changes are the hallmark of the secretory phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Hormonal and morphological changes during the normal menstrual cycle (A) and unopposed 
oestrogen exposure leads to proliferation and invasion of endometrial cancer (B).      
Adapted from van der Horst et al.
3
 and Cloke et al.
7
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     Proliferative phase    Secretory phase 
A 
B 
Invasion 
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1.1.5 Proliferative phase endometrium 
 
The proliferative phase endometrium is characterised by the oestrogen-driven re-
epithelisation following menstruation.  As demonstrated in Figure 2, the 
proliferating endometrium is exposed to high levels of oestrogen with low 
circulating progesterone levels3.  The endometrium is rapidly proliferating during 
this phase; thickness increases from approximately 1mm following menstruation to 
4mm at the time of ovulation.  The primary purpose of this phase is to re-assemble 
the cellular machinery necessary for the dynamic processes occurring later in the 
cycle10. 
 
The histology of the glands reflects the state of re-generation of the endometrium.  
The first glands to develop are characteristically straight and relatively 
undifferentiated.  These become increasingly long and tortuous as the proliferation 
continues10.  By the end of the proliferative phase, some degree of 
pseudostratification of the epithelium can be noted.  The number of mitotic figures 
reflects the increasing levels of proliferation as the phase progresses.   
 
The induction of proliferation by unopposed oestrogen exposure in the proliferative 
phase, is the closest that the benign endometrium comes to mimicking the 
conditions during endometrial carcinogenesis. 
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1.1.6 Hormone receptors 
 
The steroid hormone receptors have a key role in the hormonal regulation of the 
endometrium.  The actions of these receptors are mediated by both genomic and 
non-genomic signalling10, resulting in differential expression across the layers of the 
endometrium, time during the cycle and levels of circulating hormones (Table 1).   
 
1.1.6.1. Oestrogen receptor 
 
Oestrogen is necessary for the essential processes of the normal functioning of the 
endometrium including proliferation and vascularisation17.  Oestrogen receptor (ER) 
is expressed in both the epithelial glands and stroma of the endometrium.  The two 
subtypes of ER α and β appear to have distinct functional roles18.  ERα is known to 
up-regulate progesterone receptor and oestrogen-induced proliferation.  ERα also 
has well-defined roles in endometrial carcinoma.  The role of ERβ is far less clear19, 
and it has been postulated that balanced co-expression of both the subtypes are an 
important factor in endometrial carcinogenesis18.  In the normal endometrium, both 
ERα and ERβ are expressed in the in the epithelial glands and the stroma.  Expression 
in the basalis does not appear to change during the menstrual cycle.  However, 
expression in the epithelial glands in the functionalis layer decreased during the 
secretory phase, whilst stromal expression remained stable20, 21.   
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1.1.6.2. Progesterone receptor 
 
Progesterone receptor (PR) also has two subtypes (A and B)22.  Expression is primarily 
regulated by oestrogen, resulting in PR induction in the proliferative phase22.  This 
expression is down-regulated by its own ligand due to a negative-feedback loop.  
Consequently, expression of both subtypes is significantly reduced in the glands 
during the secretory phase, due to the dominant hormone being progesterone23.  The 
basalis of the endometrium appears to be differently regulated, with PR being 
expressed by both the epithelial and stromal cells throughout the cycle22.  The 
functional role of PR must be considered separately to its expression.  It has been 
demonstrated using the Ishikawa cell line that glandular expression is not sufficient 
for a response to progesterone, and that stromal PR is a necessary condition15.     
 
1.1.6.3. Androgen receptor 
 
Despite the lack of evidence currently available on the role of androgens in the 
endometrium7, it is becoming increasingly apparent that together with oestrogen and 
progesterone, androgens may play an important role in the regulation of the 
menstrual cycle22.  Androgen receptors are predominantly expressed in the stromal 
compartment of the endometrium22.  The available literature suggests that a rise in 
AR corresponds with a fall in progesterone levels in the proliferative phase.  This has 
been confirmed by in vitro studies using a well-differentiated cancer cell-line 
(Ishikawa) with primary stromal cells24.  Whilst these experiments were not 
performed on normal cells, the Ishikawa cell line is the currently accepted surrogate 
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for understanding hormonal regulation in the endometrium, as there is not a benign 
cell-line available25.  It would also appear that long-term progesterone treatment 
results in expression of AR in glandular epithelial cells26.  Studies in non-human 
primate endometrium suggest that there is a complex interplay between the well-
described oestrogen/progesterone mediated endometrial proliferation and 
differentiation and AR27.  The androgen 5α-dihydrotestosterone (DHT) has been 
demonstrated to antagonise the proliferative effects of oestrogen, and there would 
appear to be considerable overlap in the genes which they regulate28.  It has been 
postulated that up-regulation of AR in glandular epithelium is a key component in the 
anti-proliferative effects induced by progesterone26, 29.   
 
Table 1:  Summary of the immunolocalisation of steroid hormone receptors in the functional layer 
of the human endometrium during the normal menstrual cycle.  Adapted from Critchley et al. 
2009
22
. 
 
 
 
 
 
 
 
 
Steroid 
receptor 
Glands  Stroma  Endothelium  
ERα Positive, reduced during secretory phase Positive Negative 
ERβ Positive, reduced during secretory phase Positive Positive 
PR Positive, reduced during secretory phase Positive Negative 
AR Negative except after progesterone 
treatment. 
Positive Negative 
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1.1.7 Menopause    
 
The endometrium is physiologically designed to respond to oestrogen and oestrogen-
like molecules.  In the absence of oestrogen, the endometrium becomes thin, 
atrophic, and unable to respond to progesterone30.  Menopause, literally “cease in 
menstruation”, results from ovarian failure, and is diagnosed in retrospect following 
12 months of amenorrhoea.  During the peri-menopausal period, ovarian function 
decreases creating an imbalance in the hypothalamic-pituitary-ovarian axis.  A lack in 
circulating oestrogen results in the loss of the luteinizing hormone surge, which in 
turn causes prolonged follicular phases and anovulatory cycles10. 
   
During this phase, the histology of the endometrium reflects the hormonal status of 
the woman10.  Once ovarian function has ceased, the post-menopausal endometrium 
still contains the luminal epithelium, stroma and glands.  However, these glands are 
small and tubular, and the stroma resembles that of the pre-menopausal basalis12.  
Ultrasonic measurements of the thin post-menopausal endometrium range from 1-
5mms in healthy women.  This is in contrast to the 15mm thick secretory phase 
endometrium in young women.  However, with the adequate hormonal 
supplementation, a fully functional endometrial functionalis layer can be regenerated 
from this thin post-menopausal endometrium31 sufficient to carry a pregnancy to 
term32. 
 
Despite the atrophy that is the hallmark of the post-menopausal endometrium, 
nearly half of all endometria continue to show a weak proliferative pattern, either 
focal or diffuse, for many years following the cease of menstruation.   This is probably 
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due to continuous low-level oestrogenic stimulation.  Sivridis et al..33 outlined criteria 
for further sub-dividing the post-menopausal endometrium according to the 
proliferative profile. 
 
 Atrophic and inactive endometria:  endometrium is deprived of a functionalis 
layer and consists exclusively of a thin basalis with a few narrow tubular glands, 
lined by cuboidal indeterminate epithelium, showing neither proliferative nor 
secretory activity.   
A frequent variant of this structure included tubular atrophy.  An atrophic 
endometrium showed cystically dilated glands, lined by flattened indeterminate 
type epithelium.  
 
 Atrophic/weakly proliferative endometria:   
 Shallow endometrium 2.2mm thick with loss of distinction between the 
basal and functional layer. 
 Proliferative type tortuous endometrial glands.  Tall columnar 
pseudostratified epithelium, oval nuclei, and very infrequent mitoses. 
 Dense, fibrotic endometrial stroma, devoid of mitoses. 
 
 Mixed:  largely atrophic and inactive endometria which show focal areas of 
weakly proliferative glands. 
 
The majority of cancers are related to endometrial atrophy, which in turn originate 
from weakly proliferative glands.  Aromatase catalyses the peripheral aromatisation 
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of adrenal androstenedione to oestrone34.  This process increases with body weight 
and age due to increased specific activity of aromatase.  These factors appear to be 
additive in their effect; both factors are often present in patients.  Despite being less 
potent than oestrogen, oestrone is the single most important oestrogenic compound 
in endometrial carcinogenesis. 
 
In the absence of an operational ER system, oestrogenic stimulation would be 
ineffective.  The post-menopausal endometrium retains its low potential for 
carcinogenesis via the weak proliferative activity seen in many glands.  86% of non-
malignant tissue without neoplastic features adjacent to endometrial carcinomas 
demonstrated a focally proliferative pattern33.  It is likely that the minority which did 
not display proliferative foci, were not oestrogen independent, but rather that the 
proliferative foci had been obliterated by the invading tumours. 
 
1.1.7.1. Androgen in the post-menopausal endometrium  
 
Following the cessation of ovarian activity, circulating blood and endometrial levels of 
estradiol dramatically decrease, resulting in the onset of menopausal symptoms 
(Figure 3).  Residual circulating oestrogen levels are maintained by extra-ovarian 
conversion6; cytochrome p450 aromatase catalyses the peripheral aromatisation of 
adrenal androstenedione to oestrone.  Androgen (androstendione and testosterone) 
levels only slightly reduce during this period, and are converted to oestrones.  There 
is conflicting evidence on whether the adrenal glands or the ovaries are the main 
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source of circulating androgens in the post-menopausal endometrium; it is likely that 
both sites contribute to overall levels6.   
 
Endometrial adenocarcinoma is a disease of the post-menopausal endometrium, and 
since androgens are the dominant hormone following ovarian failure, it has been 
postulated that they have a role in endometrial carcinogenesis35.  Androgens have 
been proposed to have a direct, AR-mediated impact in addition to an indirect, ER 
mediated impact on endometrial proliferation and inflammation35.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Testosterone in the menopause.  Changes in levels of total testosterone (1), total estradiol (2) 
and their relative ratio (3) during the menopausal transition.  A)  Early reproductive stage.  B)  Late 
reproductive stage.  C)  Early menopausal transition.  D)  Late menopausal transition.  E)  Within 1 year of 
menopause.  F)  Within 5 years of menopause.  G)  5+ years since menopause.  Adapted from Yasui et al. 
2012
6 
1 
3 
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1.2. Endometrial carcinoma 
 
Endometrial cancer can be broadly divided into two categories; type 1 and 24.  
Bokhman et al.. first designated these types because they show significant 
demographic, pathological and clinical differences.  The majority of all endometrial 
carcinoma cases (approximately 80%), are the oestrogen dependent type 1 
endometrioid adenocarcinomas.  
 
 Type 1 
- Endometrioid adenocarcinoma 
- With squamous differentiation 
- Villo-glandular 
- Secretory 
- With ciliated cells. 
 
Type 2 
- Papillary serous adenocarcinoma 
- Clear cell adenocarcinoma 
- Mucinous adenocarcinoma 
- Undifferentiated carcinoma 
- Mixed carcinoma  
1.2.1 Epidemiology 
 
Endometrial carcinoma is the most common gynaecological cancer, and the fourth 
most common cancer in women.  With a lifetime risk of 1 in 4636, it is almost twice 
as common as ovarian cancer.  This is primarily a disease of post-menopausal 
women, with 93% of cases being diagnosed in women over the age of 50, with a 
peak incidence of 83 per 100,000 in women in their early 70s.  The epidemiology of 
this disease has varied greatly over the past forty years, with large variations in both 
incidence and mortality.   
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From the late 1970s onwards the mortality rates plummeted by over a third, only to 
rise again by a fifth during the new millennium to become the 9th most common 
cause of cancer death among women37.  Similarly the age-standardised mortality 
rates remained virtually stable until the late 1990s, but have since increased by over 
40%.  Currently there are approximately 8000 new cases a year in the UK which 
accounts for almost 2000 deaths, but this is set to increase.  It would appear that 
the improvements seen due to surgical improvements have been counteracted by 
the continual rise in incidence and lack of effective non-surgical options.  In fact the 
5-year survival rates have remained stable in recent years 1994-200438, despite the 
significant improvements seen in other malignancies. 
 
Multiple studies have pointed to a concerning rise in incidence.  An age-period-
cohort analysis of epidemiological data in Norway have predicted that incidence 
rates of endometrial cancer will increase by up to 100% between 2007-202539.  It 
has even been reported that in 2015, the incidence will be twice those of 200538. 
This concerning level of increasing incidence across the developed world, is 
primarily attributable to increasing life expectancy coupled with the insidious 
continual rise in body mass index (BMI)39. 
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1.2.2 Risk factors4,40 
 
The primary risk factors for type 1 endometrial cancer are those associated with 
excessive exposure to oestrogen.  The key risk factors include increasing age, 
obesity, early menarche and late menopause as well as low parity. 
 
- Polycystic ovarian syndrome 
- Family history 
- Lynch syndrome 
- Oestrogen secreting tumours 
- Diabetes mellitus 
- Hypertension 
- History of breast cancer 
- Immunodeficiency 
- Unopposed oestrogen only 
hormone replacement therapy 
- Tamoxifen therapy 
- Dietary factors 
- Previous radiotherapy 
 
Protective factors include cigarette smoking, combined oral contraception for at 
least one year, and grand multiparity. 
 
Obesity is the single most important independent risk factor for endometrial cancer 
for a number of reasons, delivering a 3.5-fold increased risk41.  In fact it is estimated 
that 70-90% of women diagnosed with endometrial cancers are overweight, and a 
growing number of these cases are attributed to obesity41.  In pre-menopausal 
women, obesity can disrupt the normal menstrual cycle by causing insulin 
resistance, ovarian androgen excess and chronic progesterone deficiency42.  In post-
menopausal women, circulating weak oestrogenic compound oestrone is derived 
from the conversion of androgens of both adrenal and androgen origin to oestrogen 
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by extra-ovarian aromatisation in peripheral adipose tissues; in obese women this 
can cause a hyper-oestrogenic state.  These high levels of oestrogen unopposed by 
progesterone, via oestrogen receptors, induce endometrial cell proliferation, 
therefore increase the likelihood of mutations41. 
 
1.2.3 Clinical features4 
 
Classically the hallmark of endometrial carcinoma is post-menopausal bleeding; in 
pre- and peri-menopausal women, this may present as intermenstrual/irregular 
bleeding.  Other clinical features include pain, vaginal discharge, and pyometra, 
which can be associated with advanced disease.  Early detection by awareness of 
symptoms is crucial for good management and prognosis.  Survival for early stage 
disease is very good; however, this drops to 45% 5-year survival in Stage III and 25% 
in Stage IV43.  Consequently, all patients presenting with post-menopausal bleeding 
should have a transvaginal ultrasound scan and endometrial biopsy as a minimum; 
the gold standard is hysteroscopy and biopsy44 (Figure 4).  Definitive diagnosis of 
endometrial cancer is histological. 
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Figure 4:  NICE guidelines for the diagnosis of endometrial adenocarcinoma.  Adapted from Saso et 
al.
4
. 
 
1.2.4 Pathology and staging  
 
The International Federation of Gynaecology and Obstetrics (FIGO) classification of 
grading and staging in endometrial cancer is currently the most widely accepted 
method,45 and remains the most useful prognostic guide (Table 2 and 3).  Low and 
high grade cancers can be distinguished by the percentage of solid or non-glandular 
areas, pattern of invasion and the presence or absence of tumour necrosis43.  The 
level of differentiation with the cancer cells is an important prognostic factor.  Since 
well differentiated cells usually maintain their steroid receptors, and therefore their 
receptivity to hormones, it is not surprising that poorly differentiated tumours are 
associated with deep myometrial invasion and metastasis46.  
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Table 2:  FIGO descriptors of grading of endometrial adenocarcinoma.  Adapted from Saso et al. 
4
. 
 
 
 
 
 
 
Staging is performed surgically, based on the operative findings at hysterectomy.  
The criteria are outlined below. 
 
Table 3:  FIGO description of staging in endometrial adenocarcinoma.  Adapted from Saso et al. 
2011
4
 
FIGO Grade Description 
Grade 1 <5% of solid/non-glandular areas 
Grade 2 6-50% of solid/non-glandular areas 
Grade 3 >50% of solid/non-glandular areas 
FIGO stage Description 
Stage 1 
Stage 1A 
Stage 1B 
Tumour confined to the corpus uteri 
No or less than half myometrial invasion 
Invasion equal to or more than half of the myometrium 
Stage 2 Tumour invades cervical stroma but does not extend beyond the uterus 
Stage 3 
Stage 3A 
Stage 3B 
Stage 3C 
Stage 3C1 
Stage 3C2 
Local and/or regional spread of the tumour 
Tumour invades the serosa of the corpus uteri and/or adnexae 
Vaginal and/or parametrial involvement 
Metastases to pelvic and/or para-aortic lymph nodes 
Positive pelvic nodes 
Positive para-aortic lymph nodes with or without positive pelvic lymph 
nodes 
Stage 4 
Stage 4A 
Stage 4B 
Tumour invades bladder and/or bowel mucosa, and/or distant metastases 
Tumour invasion of bladder and/or bowel mucosa 
Distant metastases, including intra-abdominal metastases and/or inguinal 
lymph nodes 
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The distant spread of disease from the uterine cavity to other tissues either by 
invasion or metastasis is the main cause of death in endometrial cancer.  In 
endometrial cancer, spread is primarily by local invasion to the myometrium, 
fallopian tubes, cervix, vagina, bladder and rectum.  Lymphatic spread to the pelvic, 
para-aortic and inguinal lymph glands is also common.  Despite recent advances in 
treatment and patient care advanced stage disease has a very poor prognosis43, 46, 47 
(Table 4).   
Table 4:  Proportion of cases diagnosed by stage, and the 5-year survival rates by stage.   Adapted 
from Bradford et al. 2013
47
 
  
 
 
 
 
 
 
1.2.5 Management 
 
The management of endometrial cancer is primarily based on the stage at which it 
is diagnosed (Figure 5).  Primarily the management is surgical; total abdominal 
hysterectomy with bilateral salpingo-oophrectomy, with peritoneal washings47.  In 
advanced disease, pelvic and para-aortic lymphadenectomy and omentectomy can 
also be performed42.   
 
The use of adjuvant therapy in localised endometrial cancer has been widely 
discussed, and no consensus has been achieved.  The role of radiotherapy in 
 Stage at presentation (%) 5-year survival rate (%) 
Stage I 73 85-90 
Stage II 11 70 
Stage III 13 40-50 
Stage IV 3 15-20 
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endometrial cancer remains unclear48, but is frequently used in advanced disease 
especially in the palliative setting. 
 
 
 
 
 
 
 
 
1.2.6 Model of pathogenesis 
 
Carcinogenesis in the endometrium requires the accumulation of multiple 
molecular changes in common with all cancers.  The precise mechanisms of how 
known risk factors, hormonal imbalance for example, contribute to carcinogenesis is 
poorly understood40.  The characteristic feature of endometrial carcinogenesis is 
disruption of the glandular architecture, followed by glandular crowding and loss of 
peri-glandular stroma10.  These histological features disrupt normal homeostasis by 
altering the paracrine mechanisms, as the stroma plays a key role in hormonal 
regulations15.   
 
The single most important risk factor for Type 1 carcinomas is prolonged oestrogen 
exposure, with 40% of cancers being directly attributed to obesity40.  During a 
normally regulated cycle, progesterone provides a counter-balance to high 
oestrogen levels during the secretory phase.  If there is an imbalance in this system, 
either due to low progesterone levels or inappropriately high oestrogen levels, the 
Figure 5:  Management options for endometrial adenocarcinoma.  Adapted from Saso et al.
4
. 
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oestrogen mediated proliferative effect becomes dominant leading to endometrial 
hyperplasia.  In fact progesterone appears to inhibit epithelial to mesenchymal cell 
transition; loss of progesterone signalling (which frequently occurs in progressive 
disease) releases the inhibition, and permits tumour progression49.    Endometrial 
adenocarcinoma does have a related pre-malignant hyperplastic stage, but is 
certainly not present in all cases33.  Whilst it certainly holds an important role, 
oestrogen alone is not sufficient for tumorigenesis – somatic mutations are also 
required40. 
 
The genetic mutations required for carcinogenesis are accumulative, with no single 
mutation being sufficient alone.  In the endometrium, common genetic mutations 
include adenomatous polyposis coli (APC), phosphatase and tensin homologue 
(PTEN) and β-catenin50.  The DNA mis-match repair genes (MLH1, MSH2, MSH) are 
also often implicated,40 as are tumour protein 53 (TP53) and V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS).51 
 
Possibly the single most important feature of endometrial carcinogenesis is 
aberrations in the canonical Wnt/β-catenin pathway, which may be inappropriately 
induced by excess oestrogen as would happen during the proliferative phase of the 
normal menstrual cycle. 
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1.3. Wnt-related proteins 
 
1.3.1 The canonical Wnt/β-catenin pathway 
 
The canonical Wnt/β-catenin pathway has long been known to be a key regulator in 
development, disease and homeostasis.  There are three pathways believed to be 
activated by Wnt, of which the canonical pathway is the best understood52.  The 
canonical Wnt pathway promotes cell proliferation and tissue expansion, controlling 
fate determination and terminal differentiation52. 
 
The cytoplasmic protein β-catenin lies at the centre of the canonical Wnt/β-catenin 
cascade (Figure 6).  In the absence of Wnt activation, β-catenin is bound by the 
destruction complex which is composed of the tumour suppressors adenomatous 
polyposis coli (APC) and axin.  The kinases CK1 and GSK1 from the destruction 
complex then phosphorylate β-catenin, which is then targeted for proteosomal 
degradation1.  On the other hand, if Wnt receptors are occupied, the kinase activity 
of the destruction complex is inhibited, allowing β-catenin to accumulate and travel 
to the nucleus where it binds to the N-terminus of the DNA-binding proteins of the 
Tcf/Lef family1.  β-catenin converts Tcf/Lef  factors into transcriptional activators, 
albeit transiently; this facilitates the transcription of the down-stream Wnt genes.  
Whilst it is accepted that once stabilised by Wnt signals, β-catenin translocates to 
the nucleus in order to reprogram the responding cell, there is no consensus on the 
mechanisms by which this occurs52.  In some cases, cells undergoing Wnt signalling 
show an increased β-catenin expression, rather than a nuclear preference52. 
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In addition to its signalling properties, β-catenin  is also a key component of the 
adherens junctions of simple epithelial cells52, 53.  It remains unclear whether the 
adhesive and signalling properties are inter-connected; in other organisms these 
functions are performed by different homologs52.  It is hypothesized that when first 
synthesized, β-catenin is made available to the adhesions junction.  When this pool 
is saturated, the free cytoplasmic β-catenin is degraded by the destruction complex; 
only this highly unstable pool is regulated by the Wnt signals52. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: The canonical Wnt/β-catenin pathway.  Left panel:  In the absence of Wnt signalling, β-
catenin is bound to the destruction complex which leads to its degradation.  β-catenin also binds 
to cadherins and regulates cell-cell adhesion.  Right panel:  In the presence of Wnt signalling, β-
catenin translocates to the nucleus, where it binds to Lef/Tcf transcription factors, and causes 
tramscription of downstream proliferative genes.  From Clevers et al.
5 
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1.3.2 Role in self-renewing tissues 
 
In many self-renewing tissues, such as the gut, hair follicles, haemopoietic system, 
bone and endometrium, the Wnt pathway remains vital after development and 
continues to be essential throughout life52.  Wnt signalling has been shown to be 
involved in regulating progenitor cell populations in diverse tissues, including the 
intestine5.    
 
The intestinal and endometrial epithelium share striking similarities12.  They are 
both dynamic, highly proliferative tissues that rapidly renew. The intestinal 
epithelium is arranged along the crypt-villus axis in a monolayer5.  Like the basalis of 
the endometrial glands, the crypts of Lieberkuhn contain the stem/progenitor cells 
(Figure 7).  These produce daughter cells which migrate upwards from the crypt 
towards the villus tip and differentiate into the differentiated cells; enterocytes, 
goblet and enteroendocrine cells54.  In the gut Wnt proteins are expressed by the 
epithelial glands, but not the surrounding mesenchyme; they promote the 
proliferation of the progenitor cells as well as promoting terminal differentiation of 
the Paneth cells52.  It is currently thought that the Wnt pathway is the single most 
important regulator of cell fate in the crypt-villus axis5.  In another similarity 
between the two epithelial tissues, the stem-like progenitor cells of the intestine 
also reside in the base of the glands5. 
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1.3.3 Endometrial physiology 
 
The development of the Mϋllerian duct is dependent on correct functioning of the 
Wnt pathway; in the absence of Wnt proteins including Wnt4, 9b, 5a and 7a, 
development will cease at key times3.   
 
A functional canonical Wnt/β-catenin pathway has recently been demonstrated, in 
both the pre- and post-menopausal normal endometrium32.  It is hypothesized that 
oestrogens induce Wnt/β-catenin expression during the proliferative phase, and 
progestagens inhibit it during the secretory phase, providing a counter-balance3.  
This is supported by β-catenin expression.  Nuclear staining is seen in the 
Figure 7:  Intestinal progenitor cells reside in the base of intestinal crypts.  Normal Wnt signalling 
influences the proliferation and renewal of stem and progenitor cells.  Uncontrolled Wnt signalling (red 
arrow) leads to constitutive renewal and aberrant expansion of the stem cell pool, or confer stem cell 
behaviour pm the progenitor cell pool.  These changes can lead to the formation of cancerous tissues 
(cancerous cells are denoted in red).  From Reya et al.
1 
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proliferative phase, but mainly cytoplasmic and junctional staining are seen during 
the secretory phase50.  This phasic change in localisation would suggest a role for 
the sex steroid hormones in controlling Wnt/β-catenin staining50; an interaction has 
been demonstrated in an in vivo model 55, but further work is required.   
 
The putative endometrial stem/progenitor cell is thought to be located in the 
basalis of the pre-menopausal endometrium, and is therefore retained through 
both menstruation and the menopause32.  Differential expression of BMP, NOTCH, 
Hedgehog, and FGF signalling pathways in conjunction with Wnt-related genes 
suggest cross-talk and the possible existence of stem cell signalling networks in a 
similar fashion to that found in the intestine32.  One such interaction may involve 
telomerase, which is thought to play a key role in the endometrium56, but has also 
been  suggested to be a co-factor of β-catenin in order to prevent the undermining 
of Wnt-regulation57. 
1.3.3.1. Ovarian steroid hormones and the canonical Wnt/β-catenin pathway 
 
Hormonal regulation through the hypothalamic-pituitary-ovarian axis has long been 
known to be vital to regulation of the menstrual cycle, via oestrogen-induced 
proliferation and progesterone-induced differentiation58.  The signalling pathways 
through which this is mediated are far less well understood. 
 
Endometrial proliferation appears to be regulated by a combination of oestrogen 
stimulation and Wnt signalling.  Estradiol can induce β-catenin stabilisation, and 
therefore transcription of down-stream proliferative genes.  Inhibition of Wnt 
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signalling also results in the abolition of estradiol-induced proliferation40.  These 
two mechanisms are inextricably linked, with ERα acting as a transcription factor for 
the Wnt ligands Wnt4, Wnt5a, and Wnt7a.  Estradiol appears to be able to affect 
the transcription of Wnt target genes without directly interacting with oestrogen 
response elements at the DNA level59. 
 
Progesterone can act as a profound inhibitor of Wnt/β-catenin signalling60.  This 
may be a result of induction of DKK1 and FOXO1, both of which are important Wnt 
inhibitors61.  Wnt/β-catenin may also act down-stream to the Hedgehog signalling 
pathway which is sex steroid hormone regulated; down-regulated by progesterone, 
and up-regulated by oestrogen40, 59.  It is hypothesized that inhibition of the Wnt 
pathway by progesterone is an important anti-progression mechanism in 
endometrial cancer49.  Loss of progesterone signalling leads to enhanced Wnt/β-
catenin signalling in progressive disease3.   
 
The relationship between androgens and the Wnt/β-catenin pathway have been 
extensively studied in some tissues; this does not extend to the endometrium 
where there is scant evidence62.  Androgen receptor and the Wnt/β-catenin 
pathway appears to interact during progression of prostate cancer63, although this 
may not be the case in benign tissue.  AR and β-catenin are dynamically linked; β-
catenin can perform as a co-activator of AR, and AR may be involved in nuclear co-
trafficking and transrepression of β-catenin in a variety of tissue types including 
prostate, colon and neurones64.  
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1.3.4 Role in cancer 
 
Despite being essential to life in some tissues, mutations along the Wnt pathway 
can disrupt homeostasis and cause pathologies including cancer52.  The 
demonstration of an interaction between β-catenin and APC, was the first link 
between human cancer and the Wnt/β-catenin52.  In colon cancer, loss of APC is one 
of the first mutations to occur which results in constitutive activation of the Wnt 
pathway, as the destruction complex can no longer function. 
 
The evidence of a role for Wnt in endometrial adenocarcinoma is growing, and it is 
likely that Wnt activation is likely to play a role in carcinogenesis.  The Wnt pathway 
has many self-regulating aspects, as many Wnt-downstream proteins have positive 
and negative regulating properties52.  Many members of the pathway can 
accumulate loss- and gain-of-function mutations, which among others has lead APC 
to be identified as a tumour suppressor, and β-catenin as an oncogene40.  
Approximately 40% of well-differentiated endometrial adenocarcinomas 
demonstrate nuclear β-catenin staining suggestive of an activated Wnt pathway3.  
One contributory factor is the frequency of APC mutations,  which has been 
reported to be as high as 43%51.  In addition to its role in the destruction complex, 
APC regulates other essential processes including cell proliferation, death, 
differentiation, migration and adhesion51.  In addition, activating mutations in β-
catenin itself have been reported in 15-40% of endometrial tumours65, 66.      
 
Mouse models have shown that activation of the Wnt pathway can induce 
endometrial hyperplasia and affect oestrogen signalling51.   Hormonal signalling 
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pathways require correct epithelial-stromal cross-talk, in which Wnt plays an 
important role.  However, Wnt activation alone was not sufficient for full malignant 
transformation. 
 
1.3.5 SOX9 
 
The sex-determining region Y box (SOX) factors are a large family of transcription 
factors that share a homologous high-mobility group DNA-binding domain67.  This 
family is divided into 8 groups (A-H), of which SOX9 belongs to group E.  SOX9 is 
known to have many important and diverse developmental roles including 
chondrogenesis, male gonads, neural crest and spinal cord glial cells67.  SOX9 is 
capable of causing diverse disease states due to its roles in controlling the 
pericellular environment, cell differentiation and proliferation.  The molecular 
mechanisms of this range from the transcription level to post-translational 
modification, nuclear transport and co-factor interaction68.  
 
SOX9 is also important in the maintenance of tissues, most notably for its regulatory 
role in the canonical Wnt/β-catenin pathway.  In the intestine, SOX9 is expressed in 
the stem/progenitor cells of the rapidly proliferating intestinal crypts, and is 
required for Paneth cell differentiation68-70.  It is also likely that SOX9 may regulate 
the number of stem cells in the intestinal epithelium; SOX9 knock-down mice 
express more Musashi-expressing cells70.   
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1.3.5.1. SOX9 is a modulator of the Wnt/β-catenin pathway 
 
The SOX family of transcription factors are increasingly being recognised as key 
modulators of the canonical Wnt/β-catenin pathway.  The expression of SOX9 and 
Wnt proteins are inextricably linked, with SOX9 expression in the mouse intestine 
being dependent on Wnt signalling70.  The expression pattern of SOX9 is suggestive 
of a complex transcriptional regulation, and there have been a diverse range of Wnt 
associations described in the literature.  SOX9 has been described as both a Wnt 
transcriptional target and a key canonical Wnt pathway regulator69.   
 
In the intestine, the expression of SOX9 mirrors the domain of epithelial cells 
stimulated by Wnt molecules.  The TCF4-β-catenin complex is necessary for the 
expression of SOX9, which has been confirmed in knock-out studies using TCF4-null 
mice71.  However, SOX9 subsequently locally attenuates the expression of Wnt-
target genes, thus regulating Wnt-stimulated proliferation70.  SOX9 has therefore 
been proposed as a gatekeeper of canonical Wnt-pathway activation, although 
several mechanisms have been described.  SOX9 has been demonstrated to down-
regulate70, and in some studies to, inhibit72 β-catenin/TCF-dependent 
transcription70.  In addition, SOX9 both inhibits the activation of the β-catenin-
dependent promoters and stimulates β-catenin degradation73.  In chondrocytes, up-
regulated SOX9 produces the same phenotype as a loss of β-catenin function.  
Conversely, loss of SOX9 expression resembles constitutively activated β-catenin.  
Regardless of the exact mechanism, a classical negative feedback loop is well 
described in the murine intestinal epithelium69, and ensures that Wnt-stimulated 
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proliferation is kept in check70, 71.  Aberrations in this closely controlled relationship 
have been implicated in the pathogenesis of several cancers. 
 
1.3.5.2. SOX9 is implicated in carcinogenesis  
 
SOX9 expression has been reported in various human malignancies, including lung 
adenomas and prostate carcinomas67.  The possible significance of this has not yet 
been fully determined, and it would appear that SOX9 has differing roles between 
types of malignancy67.  One of its roles in carcinogenesis may be involvement in 
epithelial-to-mesenchymal transition (EMT).  EMT is one of the processes which 
permit metastasis, due to previously immobile epithelial cells gaining mesenchymal 
characteristics74.  SOX9 is known to be involved in EMT during normal development, 
but is also speculated to be involved in EMT in both prostate and colon cancer68. 
 
The currently available data propose opposing roles for SOX9 in malignancy.  For 
example, up-regulation in lung adenomas results in gain of tumour growth potential 
and tumorigenicity67. However, in prostate carcinoma elevated expression results in 
a decreased rate of cellular proliferation, cell cycle arrest in grade 0/1 cancers and 
an increased sensitivity to apoptosis67. Moreover, SOX9 has been proposed to both 
induce and inhibit cell proliferation.  It is necessary to consider possible interactions 
with signalling pathways in order to fully understand the implications of SOX9 
expression in malignancy68.  During normal chondrogenesis, SOX9 is regulated by 
Wnt, TGF-β, Notch and FGF all of which have been investigated in relation to 
malignancy. 
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1.3.5.3. The expression of SOX9 in the endometrium 
 
The role of SOX9 in the endometrium is largely undetermined, but it has been 
suggested that its expression may play a key role in the establishment and 
maintenance of characteristic phenotypes of glandular cells during the menstrual 
cycle67.  Saegusa et al. have reported nuclear SOX9 staining in a subset of epithelial, 
but not stromal endometrial cells.  They described an increase from normal, to 
hyperplastic, to malignant samples, with a similar correlation between increasing 
grade67.  There also appears to be a bi-phasic up-regulation during the proliferative 
and late-secretory phases of the normal endometrial cycle12, 67.  However, a high 
level expression of SOX9 in the post-menopausal endometrium has been 
subsequently reported12, which was not investigated by Saegusa et al..  The 
emerging role for SOX9 in keeping proliferation under tight regulatory control, 
thereby suppressing Wnt mediated proliferation would support a high SOX9 
expression in the largely atrophic post-menopausal endometrium12.  In addition, 
SOX9 appears to be down-regulated by oestrogen, and therefore an elevated 
expression in the hypo-oestrogenic could be expected75.  SOX9 may consequently 
act to prevent the development of hyperplasia, as loss of intestinal SOX9 leads to 
hyperplasia70.  The relative expression between post-menopausal and malignant 
endometrium remains unknown. 
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1.3.6 NAP1L1 
 
 
Nucleosome assembly protein 1-like 1 (NAP1L1), is a nuclear protein involved in 
modulating chromatin formation and contributes to the regulation of cell 
proliferation.  To date the exact function of NAP1L1 is not clear although it is 
speculated to be involved in regulating DNA replication, gene expression, and cell 
growth76.  NAP1L1 is the human equivalent to the yeast NAP1 gene77, whose roles 
include; histone chaperone, chromatin-assembly factor, role in tissue-specific 
transcription regulation, histone shuttling, apoptosis and cell-cycle regulation78.  
Increased expression of NAP1L1 may be related to the progression of cell growth, as 
both the mRNA and protein levels increases with the induction of cell proliferation 
in a T-lymphoid cell model77. 
 
Chromatin assembly is a vital process in the maintenance of genomic integrity79, the 
histone chaperone proteins such as NAP1L1 have 3 primary roles.  Firstly to regulate 
chromatin assembly, secondly to mediate chromatin disassembly during 
transcription and replication, and thirdly to create specialised chromatin structures 
containing histone variants79. 
 
NAP1L1 has been discussed in relation to stem-like cells in the heart.  It is suggested 
that down-regulation of NAP1L1 may facilitate the transition from stem cells into 
cardiomyocytes78.  NAP1L1 has frequently been described as a cancer-related 
protein78, showing up-regulation in both hepatoblastomas80 and breast cancer81.  
Studies have shown that the NAP1L1 gene can be used to identify, both the primary 
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hepatoblastoma tumour, but also their metastases77.  The evidence in colon cancer 
is similarly promising, with approximately 50% of cases showing over-expression.  
NAP1L1 could be considered to be a proliferation marker of colon cancer cells, and 
theoretically could be investigated as a future therapeutic target82.  Moreover in 
breast cancer, NAP1L1 has been studied as a potential marker of resistance to 
chemotherapeutic agents.  Over-expression of NAP1L1, together with NAP1L4, 
exerts a protective effect against doxorubicin-induced cytotoxicity81.  NAP1L1 has 
also been identified to induce 4-hydroxytamoxifen in the breast cancer cell line 
T37D81.  There have not been any published reports of NAP1L1 in either the normal 
or malignant endometrium. 
 
1.3.7 SFRS2 
 
Serine/arginine-rich splicing factor 2 (SFRS2) also known as splicing factor 35 (SC35), 
is one of the 8 classical83 serine/arginine-rich (SR) splicing factors.  The SR splicing 
factors are an essential component of the spliceosome, which acts to remove 
introns from precursor mRNA.  They allow alternative splicing, a fundamental 
process controlling gene expression in differentiation and development84.  The 
result of alternative splicing of pre-mRNA is to generate functionally diverse 
isoforms from a single gene, enabling cell and tissue specific gene expression in 
response to both developmental and environmental cues85.  Whilst this is usually a 
regulated step in the expression of eukaryotic genes, it can become dysregulated in 
carcinogenesis, with many cancer-associated genes being regulated by this process.  
Furthermore, many splice variants (created by the selective joining of different 
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exons) are unique to the malignant state.  Whilst the exact role that these variants 
play in the development and maintenance of a tumour is yet to be established, it 
can be hypothesized that they have potential as diagnostic indicators and 
therapeutic targets85. 
 
SFRS2 is increasingly being investigated in a variety of malignancies including 
cervical, ovarian, breast and colon, all of which have similarities with endometrial 
cancer.  There are a number of postulated roles and mechanisms; there is a marked 
induction of SFRS2 in ovarian cancer relative to normal ovarian tissue85.  
Pharmacogenomics studies have identified SFRS2 to be among a group of molecular 
determinants of sensitivity and resistance to chemotherapeutic agents including 
artesunate86, which can be used to treat both breast and colon cancers.  Expression 
of SR family members, including SFRS2, has been shown to be altered during 
mammary tumorigenesis, leading to alterations in the normal splicing of a number 
of pre-mRNA87. 
 
SFRS2 is required for the alternative splicing of KLF6, a tumour suppressor gene85, 
which has an important role in breast, prostate and colon cancers.  This has led to 
speculation as to whether SFRS2 is a proto-oncogene, and its ability to regulate the 
genes identified by Shi et al.. gives it its transforming ability85. 
 
SFRS2 showed abundant nuclear staining in cervical intraepithelial neoplasia (CIN) 3, 
with a trend of increasing over-expression throughout the grades of CIN83.  The 
results might suggest a role for SFRS2 in cervical tumour formation.  One promising 
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avenue of investigation is the use of SR proteins for diagnosis of cervical tumour 
progression; SFRS2 marks the nuclei of rapidly dividing basal epithelial cells.  In high-
grade cervical lesions, these basal cells fill the full thickness of the epithelium, giving 
a uniform staining. 
 
Epithelial cancer cells surfaces are covered by complex carbohydrates88, which 
function in both malignancy and metastasis.  Whilst no mechanism has been 
defined, it is postulated that there is a correlation between cancer-associated 
carbohydrate antigens and poor patient prognosis, including metastasis.  
Hatakeyama et al. suggest that the SFRS proteins are expressed by a subset of lung 
capillaries, and it is these which are responsible for the carbohydrate-dependent 
cancer cell colonization of the lung in the mouse.  However, they cannot exclude 
that it is another carbohydrate-binding receptor which mediates this mechanism. 
 
Merdzhanova89,90 et al. investigated whether E2F1 and its direct transcriptional 
target SFRS2 could control VEGF-A expression and pre-mRNA splicing in p53-
deficient tumour cells. The E2F family are essential for a wide range of biological 
processes, including S-phase entry and progression, DNA replication, mitosis, DNA 
repair, cell differentiation and apoptosis.  Perhaps ones of its most important roles 
in this context, is the p53-dependent down-regulation of the activity of the VEGF 
promoter under hypoxic conditions.  Mendzhanova concludes that their data 
strongly suggests that E2F1 and SFRS2 are involved in the reduction of tumour 
neovascularisation. 
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Whilst there are yet to be any investigations of SFRS2 in endometrial cancer, it is 
known to be both present in the human endometrium84, 91 and regulated by sex-
steroid hormones87.  Nie et al.. have shown that SFRS2 is present in the primate 
endometrium (human and rhesus monkey), and have postulated a role in the 
preparation of a receptive endometrium for implantation84.  Many genes identified 
as being vital to implantation require their mRNA to be spliced, which has led to a 
prediction that SFRS2 has a pivotal role for key modifications required by these 
proteins at implantation.  Progesterone is a key up-regulator of this gene, although 
no clear mechanism has been established; there does not appear to be a dose-
dependent relationship, and the presence of a fetus may be a key regulator87. 
 
1.3.8 SOX2 
 
SOX2 is another member of the high-mobility group (HMG) box of sex-determining 
region Y gene family group B92,93, 94.  SOX2 has a number of vital roles in both the 
embryonic and adult stem cells, with roles including stem cell determination, 
pluripotency, differentiation and the maintenance of a cell’s ability for proliferative 
potential93, 95, 96.  Together with OCT3/4 and NANOG, SOX2 has long been 
considered to be a master regulator of embryogenesis96. 
 
The remarkable ability of the human endometrium to regenerate is thought to arise 
from putative endometrial epithelial stem or progenitor cells located in the basalis 
glands97.  These adult stem cells are also implicated in the pathogenesis of the 
endometrial proliferative conditions including endometriosis and endometrial 
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adenocarcinoma.  Despite their importance, there are no generally accepted 
markers of the epithelial endometrial progenitor cells, although there are markers 
such as SSEA-1, CD133 and SOX2 which mark less well differentiated cells11, 12, 98.  
The accumulation of genetic mutations sufficient for malignant transformation may 
take many years.  It has been postulated that the only cells with the necessary life-
span, and therefore responsible for carcinogenesis are the adult stem/progenitor 
cells99.  
 
There are contradicting reports on the expression of SOX2 in the normal, 
endometriotic and malignant human endometrium100, 101.  The expression of a true 
stem-cell marker would be low in a tissue such as endometrium which only has a 
small sub-population of less well differentiated cells.  As such, the selection of tissue 
and sensitivity of the detection methods may adversely affect the results.    
 
SOX2 is known to be dysregulated in a variety of cancers, although its role appears 
to differ in each. It has been reported to be both down- and up-regulated in a 
diverse range of cancers from those of the gastro-intestinal tract to lung and breast 
carcinomas.  In endometrial carcinoma, studies suggest that hypermethylation of 
SOX2 and subsequent lower expression is more common in malignant samples than 
normal controls96.  This suggests that SOX2 down-regulation may play a role in 
endometrial carcinogenesis, however, since the overall expression of SOX2 was so 
low, it seems likely that it only contributes to an overall cascade of events.  It must 
be noted, that other studies have not detected SOX2 in the normal endometrium101. 
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In addition to being a stemness-related transcription factor96, SOX2 is also related to 
the canonical Wnt/β-catenin pathway102.  Epithelial-to-mesenchymal transition 
(EMT) is an essential developmental process whereby previously immobile 
epithelial cells acquire mesenchymal characteristics74.  This process also occurs 
during the migration of cancers from their primary to metastatic sites, as it allows 
the penetration of both lymphatic and blood vessels.  SOX2 has been proposed to 
regulate EMT via the Wnt/β-catenin pathway, and therefore be a key controller of 
invasive potential102.  Li et al. propose that SOX2 binds to the promoter region of β-
catenin in order to control its transcription102.  In addition to SOX2 modulating 
transcriptional responses to Wnt signalling, Wnt signalling can also regulate SOX2 
expression69.  SOX genes are increasingly being recognised as fine-tuners of Wnt 
signalling via feedback loops69. 
 
1.3.9 Ki67 
 
Ki67 is a well described marker of proliferation in the endometrial epithelial cells41, 
it is known to mark the nuclei of cells in the G1, S, G2 and M phases of the cell cycle.  
Nuclear β-catenin theoretically marks cells which are actively transcribing 
downstream Wnt-related genes, whereas Ki67 is a more direct assessment of 
proliferation. 
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Chapter 2. Project Aims and Hypotheses 
 
Aim:  To assess the activation of the canonical Wnt/β-catenin pathway via the 
presence of nuclear β-catenin in normal proliferative phase and post-menopausal 
endometrium in comparison to endometrial adenocarcinoma. 
Hypothesis:  Nuclear β-catenin expression will be seen in occasional cells of the 
normal endometrium.  Most endometrial cancer samples will demonstrate an 
activated Wnt/β-catenin pathway, therefore increase nuclear β-catenin staining. 
 
Aim:  To assess the expression of nuclear SOX9 in normal proliferative phase and 
post-menopausal endometrium, in comparison to endometrial adenocarcinoma 
samples. 
Hypothesis:  SOX9 will demonstrate a high-level of staining in the post-menopausal 
endometrium.  A lower level of expression will be seen in the proliferative phase 
and malignant samples. 
 
Aim:  To assess the expression of the Wnt-related proteins NAP1L1, SFRS2 and SOX2 
in normal proliferative phase and post-menopausal endometrium in comparison to 
endometrial adenocarcinoma.  
Hypothesis:  NAP1L1, SFRS2 and SOX2 will be expressed in both the normal and 
malignant endometrium.  Their expression will be related to nuclear β-catenin.   
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Aim:  To investigate the effects of ovarian steroid hormones on the expression of 
SOX9 in the Ishikawa endometrial carcinoma cell line. 
Hypothesis:  Ovarian steroid hormone treatment will alter SOX9 expression of the 
Ishikawa cell line.   
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Chapter 3. Materials and Methods 
3.1. Ethics 
 
Ethical approval for the collection of human endometrium was given by the 
Liverpool Adult Ethics Committee (LREC references; 09/H1005/55 and 11/H1005/4).  
All patients gave full written informed consent for taking part in the study 
(Appendix 1). 
 
3.2. Sample groups and collection 
 
All patients were identified by reviewing the elective theatre lists at the Liverpool 
Women’s Hospital.  Women who matched the inclusion and exclusion criteria (Table 
5 and 6)were approached and asked if they wished to participate in the study by 
one of the designated personnel in the research team who were trained in Good 
Clinical Practice (GCP).  Since the collected samples were surplus tissue left after 
surgical specimens had been taken for pathological diagnosis, there were no extra 
surgical procedures performed than those which were clinically necessary.  
Informed written consent was obtained together with demographic details 
including: age, BMI, smoking status, fertility history, use of hormonal treatments, 
and details of the menstrual cycle. 
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Table 5:  Principal inclusion criteria 
 
Study Group Inclusion criteria 
Proliferative o Must be aged 18-50 years. 
o Must be having regular menstrual periods. 
o Must be undergoing surgery for a benign non-endometrial 
indication at Liverpool Women’s Hospital. 
o Must be able to give valid informed written consent. 
Post-
menopausal 
o Must be over 51 years old. 
o Must be at least 12 months post-menopausal. 
o Must be undergoing surgery for a benign non-endometrial 
indication at Liverpool Women’s Hospital. 
o Must be able to give valid informed written consent. 
Cancer o Patients must be undergoing hysterectomy for endometrial 
cancer at the Liverpool Women’s Hospital. 
o Patients must be able to give valid informed written consent. 
Table 6:  Principal exclusion criteria 
 
Study Group Exclusion criteria 
Proliferative o Exogenous hormone therapy in the past three months. 
o Pregnancy; current or in the past three months. 
o Breast-feeding; currently or in the past three months. 
o History of endometriosis. 
o History of endometrial pathology. 
o History of infertility. 
Post-
menopausal 
o Exogenous hormone therapy in the past three months. 
o History of endometriosis 
o History of endometrial pathology 
Cancer o Previous chemotherapy or radiotherapy. 
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In benign cases where a hysterectomy was not always being performed and in 
endometrial cancer samples, a pipelle biopsy was always used.  Endometrial 
biopsies were collected from endometrial cancer patients and some pre-
menopausal normal women by trained members of the research team or by a 
surgeon in theatre under sterile conditions.  Once the uterus had been surgically 
removed in post-menopausal or pre-menopausal women without cancer, it was 
transferred to a clean trolley.  The anterior aspect of the uterus was opened in the 
coronal plane to expose the uterine cavity.  A small, shallow incision was used to 
remove a full thickness endometrial section containing both the myometrium and 
endometrium.  In women with cancer the uterus was not opened prior to sending 
to the pathology department due to the possibility of interference with pathological 
diagnosis. 
 
The pipelle (Laboratoire C.C.D., Paris, France) was introduced into the endometrial 
cavity, once gentle resistance was felt at the fundal area the inner piston of the 
pipelle was withdrawn thus creating a vacuum effect which draws the endometrial 
lining into the pipelle. 
 
The tissue samples for immunohistochemistry were transferred directly into a 
universal tube containing 15ml neutral buffered formalin (NBF; Sigma-Aldrich, 
Poole, UK) and incubated for a minimum of 24 hours prior to processing.  Formalin 
fixation preserves the biological sample as close to its natural state as possible.  NBF 
is about 3.7-4% formaldehyde which creates crosslinks between proteins in tissues, 
resulting in the preservation of tissue as they are found in situ.  The samples were 
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then embedded in paraffin wax using the automated Shandon Citadel 1000 
processing machine.  It dehydrates then impregnates the formalin fixed tissue with 
paraffin wax in order to maintain the natural shape and architecture of the sample 
for long term storage and sectioning.  The following processing schedule was used 
(Table 7). 
 
Table 7:  Tissue processing protocol 
 Time / mins 
10% formalin in neutral buffer 45 
60% ethanol 60 
70% ethanol 60 
90% ethanol 60 
100% ethanol 60 
100% ethanol 90 
100% ethanol 120 
Xylene 1 60 
Xylene 2 90 
Xylene 3 120 
Wax 1 150 
Wax 2 210 
  
 
Samples for RNA extraction were immediately transferred to a cryovial containing 
500μl of RNAlater (Applied Biosciences, Warrington, UK), placed on ice, and then 
stored overnight at 4°C.  The RNAlater was subsequently removed and tissue stored 
at -80°C. 
  
 
 
 
48 
 
3.2.1 Sectioning and slide preparation 
 
Sectioning 
3μm thick sections were cut using a Microm HM355 rotary microtome (Microm 
Ltds, Thame UK), floated onto a ~40°C waterbath, before being transferred to an 
aminopropyl triethoxy silane (APES) coated slide and left to dry at room 
temperature.  Slides were stored in covered boxes in order to protect from dust 
prior to being used. 
1.  
Preparation of the slide 
Slides were placed in a metal staining rack, then either heated at 60°C for one hour 
or at 37°C overnight.  This allowed the removal of moisture from under the section 
which otherwise can prevent adhesion to the slide.  Care was taken to avoid over-
baking as this can decrease target staining. 
 
The slides were then deparaffinised using xylene and gradually rehydrated using 
decreasing percentages of alcohol.  Slides are then transferred into tap water.  
Duration in each of the solutions is outlined below (Table 8).   
Table 8:  Dehydration protocol 
2.  
3.  
 
 
 
 
 Time / mins 
Xylene 1 10 
Xylene 2 10 
100% ethanol 5 
100% ethanol 5 
90%   ethanol 1 
70%   ethanol 1 
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3.2.2 Immunohistochemistry 
 
Immunohistochemistry (IHC) allows the detection of specific antigens within tissues, 
the method used here was a two-step technique using the Vector impress reagent 
kit (Vector, Peterborough, UK) (Figure 8).  This system uses a Horseradish 
Peroxidase (HRP) labelled polymer which has been conjugated with secondary 
antibodies, which is added following incubation with a primary antibody.  
Subsequent incubation with 3’3-diaminobenzidine (DAB) + substrate – chromogen 
leaves a brown-coloured precipitate. 
 
 
 
 
 
 
 
Figure 8:  Principles of immunohistochemistry 
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3.2.3 Antigen retrieval 
 
Formalin-fixation stabilises the tissue proteins by the formation of cross-links; these 
bonds maintain the tissue morphology, however, they may also alter the antigen’s 
epitopes and/or electrostatic charges.  If the epitopes are not restored, then weak 
or false-negative immunohistochemical staining may occur; restoration of the 
epitopes allows the epitope to react with the paratope of the antibody.   
 
A 10mM solution of citrate buffer was prepared and adjusted to pH 6.0.  Once the 
buffer was heated to a rolling boil in a stainless steel pressure cooker, the slide 
racks were immersed, lid engaged and the cooker allowed to come to pressure 
(indicated by elevation of a button).  After a timed period (see Table 10), the 
pressure cooker was rapidly cooled and the staining racks transferred into tap 
water. 
  
3.2.4 Immunohistochemistry 
 
Following antigen retrieval, slides were washed in Tris-buffered saline (TBS) for 5 
minutes before being immersed in a 0.3% H202 solution in TBS for 10 minutes to 
quench the endogenous peroxidase activity which could otherwise generate false-
positive signals.  The slides were then further washed in TBS twice (5 minutes each).  
A DAKO hydrophobic marker pen (DAKO, Cambridge, UK) was used to encircle the 
sections on the slides before being placed in a humidified slide chamber.  For all 
antibodies other than mouse monoclonal antibodies, 1-2 drops of 2.5% normal 
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horse serum block was added to the sections for 20 minutes.  Primary antibodies 
were diluted to the appropriate concentration using antibody diluent (TBS/0.5% 
bovine serum albumin (BSA)).  50-75μl antibody was added to each section (size 
dependent) and allowed to incubate in the humidified chamber (Table 10). 
 
Following incubation, the slides were washed twice in TBS (5 minutes each) before 
1-2 drops of labelled polymer-HRP were added per section and incubated for 30 
minutes at room temperature.  The slides underwent two further washes in TBS 
before a 30μl/1ml DAB chromogen/substrate buffer solution was added to the 
slides for 10 minutes.  The reaction was stopped by immediately immersing the 
sides in tap water.  The slides were counterstained in Gill-2 haematoxylin  
(Thermoscientific, Loughborough, UK) for 1 minute, washed in tap water then 
briefly dipped in 1% acid alcohol solution.  The slides were then run under cold tap 
water for 10 minutes before being dehydrated in increasing percentage of alcohol 
solutions and xylene (Table 9).  Cover slips were attached using the Xylene-based 
Consul Mount (Thermoscientific, Loughborough, UK), and slides allowed to dry.  
Care was taken at all stages to prevent the sections from drying out which may 
result in non-specific staining. 
Table 9:  Dewaxing protocol 
 
 
 
 
 
 
 Time / mins 
70%   ethanol 1 
90%   ethanol 1 
100% ethanol 3 
100% ethanol 3 
Xylene 1 5 
Xylene 2 10 
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Table 10:  Immunohistochemistry antibody conditions 
 
 
 
3.2.5 Controls 
 
To ensure that staining intensity remained constant between staining runs an 
internal control was used (Table 11).  Consecutive sections of positively staining 
sample were cut and included in each run.  The stained slides were then compared 
to ensure consistency of results.  A positive control was used to ensure appropriate 
positive staining intensity was observed, and a negative control (IgG matching the 
primary antibody) was performed on at least one of the sections being stained in 
each run to ensure the staining was specific.     
 
 Antibodies 
 SOX9 β-catenin NAP1L1 SFRS2 SOX2 Ki67 
Antigen retrieval / 
min 
4 2 1 1 1 4 
Host species Goat Rabbit Rabbit Rabbit Mouse Mouse 
Horse serum Yes Yes Yes Yes No No 
Concentration 1:200 1:400 1:4000 1:500 1:25 1:200 
Incubation time Overnight 2 hours Overnight Overnight Overnight Overnight 
Incubation 
temperature 
4°C 25°C 4°C 4°C 4°C 4°C 
Supplier Details R&D 
Systems, 
Abingdon, 
UK 
Cell 
Signalling 
Technology, 
Herts, UK 
Abcam, 
Cambridge, 
UK 
Abcam, 
Cambridge, 
UK 
R&D 
Systems, 
Abingdon, 
UK 
Vision 
Biosystems, 
Novocastra, 
Newcastle, 
UK 
Supplier code AF3075 9582S6 Ab33076 Ab28478 MAB2018 NCL-Ki67 
Clone     245610 MM1 
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Table 11:  Controls for immunohistochemistry 
 
Antibody External positive control Internal Positive control Negative control 
B-catenin Liver EndoCa 15-1 Rabbit IgG  
SOX9 Prostate EndoCa 15-1 Goat IgG 
SFRS2 Gut EndoCa 23-2 Rabbit IgG 
NAP1L1 Gut EndoCa 23-2 Rabbit IgG 
SOX2 Endometrial cancer EndoCa 14-5 Mouse IgG 
Ki67 Tonsil EndoCa 15-1 Mouse IgG 
 
 
 
3.2.6 Haematoxylin and eosin staining for dating and staging 
 
All specimens were stained using haematoxylin and eosin in order to analyse the 
histopathology of the sections.  The haematoxylin stains the cell nuclei blue/black, 
whereas the eosin stains the cell cytoplasm and connective tissue fibres shades of 
pink; this demonstrates the tissue structures.  The sections were reviewed blinded 
by a Consultant Gynaecologist and/or a pathologist within the department, and 
correlated with the pathology report in order to establish histological dating.  Any 
discrepancies were reviewed.  This was used in conjunction with the information 
from patients, removing any recall bias as some patients struggle to remember their 
last menstrual period.  In the case of the endometrial cancer samples, this ensured 
that the sample being stained contained malignant tissue.  Endometrial carcinomas 
are typically heterogeneous and therefore it is important to know the grade of the 
specific section being analysed.     
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3.2.7 Image analysis 
 
In order to be able to assess whether the Wnt-related proteins were differentially 
expressed in the study groups, both the staining intensity and patterns needed to 
be quantified.  For some of the proteins such as β-catenin both the intra-cellular 
location and staining intensity were required to be assessed, whereas for other such 
as SFRS2 only the intensity was necessary.  For this reason, several different analysis 
methods were employed.      
 
3.2.8 Image capture 
 
The stained sections were visualised and captured using Nikon Biophot Micoscope 
and camera head (Nikon, Tokyo, Japan).  For post-menopausal and proliferative 
samples, the functional layer of the endometrium was located and 10 consecutive 
high-power views were captured. Where full-thickness sections were used, care was 
taken to ensure that only glands within the functionalis were captured.  This was to 
ensure that the control groups were as much as direct a comparison as possible for 
the pipelle samples.  For malignant samples, 10 consecutive high-power views 
containing malignant cells were captured.   
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3.2.8.1. Percentage of positive cells 
 
For the nuclear proteins Ki67 and SOX9, and proteins such as β-catenin and SOX2 
where the intra-cellular location was important, the percentage of positive cells was 
assessed.  Initial quantification was performed using the ImageJ plug-in cell counter 
(www.rsbweb.nih.gov/ij/ version 1.48a) (Figure 9).   
 
Firstly, the endometrial glands were isolated using the selection tool.  Then, cells 
were individually selected in either red (positive) or blue (negative) and the totals 
collected.  This gives the percentage of positively stained cells within the glands.  
Extra care was taken in the malignant samples to ensure that only malignant cells 
were assessed. 
 
 
 
 
 
 
 
 
 
 
Figure 9:  Cell counting using ImageJ.  1)  Original image for analysis.  2)  Removal of stroma.  3)  Nuclei marked 
as either positive (red) or negative (blue) in A)  β-catenin staining in a cancer sample.  B)  SOX9 staining in a post-
menopausal sample 
B1 B3 B2 
A1 A3 A2 
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This technique was utilised for β-catenin and SOX2.  Following scoring all of the 
sections for these proteins, it was possible to accurately estimate the percentage of 
positively stained cells.  Where percentages of positive cells have been estimated 
(SOX9 and Ki67), they are estimated to within a 10 percentile band.  An example of 
validating this technique is shown below (Table 12).  Where discrepancies were 
noted (highlighted in green), they were acceptably small. 
 
 Table 12:  Comparison of calculated to estimated percentage positive cells 
 
 
 
 
 
 
Image Estimated percentage positive cells Calculated percentage positive cells 
1 <10% 9.9 
2 50-60% 51.3 
3 40-50% 44.0 
4 70-80% 77.3 
5 90-100% 89.7 
6 30-40% 36.6 
7 <10% 0.91 
8 90-100% 95.5 
9 <10% 5.62 
10 30-40% 27.9 
11 60-70% 64.8 
12 <10% 4.6 
13 40-50% 47.6 
14 70-80% 71.8 
15 30-40% 41.3 
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3.2.8.2. Image J colour deconvolution and area measurement 
 
The surrounding stroma was discarded using the method outlined above.  ImageJ 
has built-in vectors for haematoxylin and DAB which separate the blue 
(haematoxylin) from the brown (DAB).  Auto-threshold colour deconvolution tool 
was applied, and the area measured using the ‘area measurement’ function (Figure 
10). 
 
Estimate of stained area  =  Area of brown in 10 high-powered fields 
      Area of blue in 10 high-powered fields 
 
This is a validated and published method for accurately estimating positive 
staining103.  This method does not distinguish nuclear from cytoplasmic staining, but 
as it combines both, it provides an objective score for both NAP1L1 and SFRS2.   
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A 
B 
C 
D 
D 
Figure 12:  Colour deconvolution and area measurement using Image J.  A)  Original image for analysis.   
B)  Stroma removed.  C)  Selecting the haematoxylin and DAB (HDAB) vectors.  D)  Brown/DAB (left) and 
blue/haematoxylin (right) staining.  E)  Thresholding of area to be measured. 
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3.2.8.3. Modified QuickScore 
 
The modified QuickScore technique combines the intensity and proportion of 
staining to provide a semi-quantitative overall score for the stain (Table 13).  The 
entire functional layer or malignant area of cancer samples was assessed at high 
power and a score assigned.   
 
Table 13:  QuickScore criteria 
 
Intensity Percentage of positive cells  (%) 
0  Absent 1 <25% 
1 Weak 2 25-50% 
2 Moderate 3 50-75% 
3 Strong 4 >75% 
 
Results are scored by multiplying the percentage of positive cells by the intensity, 
the maximum score is 12.  For example if 25% of a sample was negative, 50% was 
weakly stained and 25% moderately stained, the score would be: 
 
(Absent x <25%)  +  (Weak x 50%) +  (Moderate x <25%) = QuickScore 
(0 x 1)       +   (1 x 2)   +  (2 x 3)   = 8 
 
Prior to scoring, all samples were reviewed in order to establish what staining 
intensity would constitute weak, moderate and strong staining.  Images were taken 
as described previously, and used as guide.    
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3.3. Cell culture 
 
The Ishikawa cell-line was derived from a well-differentiated grade 1 human 
endometrial adenocarcinoma (obtained from Public Health England (Salisbury, UK)) 
and was used to assess the functional role of SOX9 in vitro.   
 
The cells were maintained in DMEM/F12 (Sigma, UK), 10%FBS (BioSera, UK) 
supplemented with L-glutamine (2mM final, Sigma) and the antibiotic, PrimocinTM 
(1/500 in media; InvivoGen).  
 
For experiments involving steroids the cells were maintained in DMEM/F12 (phenol-
free, Life Technologies, UK) with 5% charcoal-stripped FCS (Sigma) for at least 72 
hours prior to the experiment. Cells were seeded at 2x 105 cells/well in 6-well tissue 
culture dishes (Nunc, Fisher Scientific, UK) in media with or without steroid 
hormones or growth hormones individually or in combination.  All experiments 
were performed in triplicate.  
 
Five ovarian steroid hormone treatments were employed in order to assess their 
effect on SOX9 expression (Figure 11).  Estradiol (E2), the highly potent synthetic 
progestagen medroxyprogesterone acetate (MPA), a combination of both E2 and 
MPA, fibroblast growth factor (FGF) and the androgen (5α-dihydrotestosterone).  
Although not an ovarian hormone, FGFs play a key role in modulating the effects of 
progesterone on the endometrium,  as well as modulating SOX9 in other tissue 
systems68. 
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The hormones were made as 1mg/ml stocks in ethanol or methanol and used at the 
indicated concentrations for 72 hours: 17 beta-estradiol (E2; 10-8M; Sigma), 
medroxyprogesterone acetate (MPA; 10-6M; Selleckchem through Stratech 
Scientific, UK), 5 alpha-dihydrotestosterone (DHT; 10-6 M; Sigma). Cells were also 
cultured in fibroblast growth factor (FGF, basic 146 aa; R&D Systems) at 50ng/ml. 
For RNA isolation, cells were harvested into TRIzol (Life Technologies, UK) 1 ml/ well 
and stored at -80oC prior to RNA extraction. 
 
Tissue culture experiments were performed in conjunction with Anthony Valentijn. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13:  Flow diagram of the cell culture experiments to assess the effect of hormonal treatments 
on the transcription of SOX9, ERα and PR. 
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3.4. RNA isolation 
 
In order to extract RNA the Pure Link RNA mini kit (Ambion, Life Technologies, 
Paisley, UK) was used.  TRIzol is a monophasic solution which contains phenol, 
guanidine isothiocynate and other components which disrupt cells and dissolves 
cellular components whilst promoting inhibition of RNases and maintaining RNA 
integrity.  Where fresh tissue was used, the tissue was first homogenised using 
Ultra-turrax (IKA Labortechnik, Staufen, Germany) for 2 mins, in 1ml TRIzol per 50-
100mg tissue to ensure that the TRIzol can work most effectively.  The adherent 
cells from culture were incubated in 1 ml TRIzol per 10 cm2 for 5 minutes and 
disrupted using a pipette tip.  Following these initial steps, the RNA extraction was 
performed using the same method. 
 
The cell lysates were incubated with TRIzol at room temperature for 5 minutes to 
allow complete disassociation of nucleoprotein complexes.  0.2mL chloroform per 1 
mL TRIzol was added to each tube and shaken vigorously for 15 seconds prior to 
being centrifuged at 12,000 x g for 15 minutes at 4°C.  This separated the mixture 
into a lower red phenol-chloroform phase, an interphase and an upper aqueous 
phase which contained the RNA. This upper phase was transferred to a fresh RNase-
free tube, to which an equal volume of 70% ethanol was added and vortexed. 
 
The PureLink RNA mini kit utilises a silica-based membrane in a spin-column, to 
which the RNA binds during purification.  The membrane is then washed using 
proprietary buffers included in the kit and eluted using RNase-free water.  Up to 
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700μl of sample was transferred to a spin cartridge, spun at 12, 000 x g for 15 
seconds at room temperature and the flow-through discarded.  This was repeated 
until the entire sample has been processed.  700μl of Wash Buffer I was added to 
the spin cartridge, spun under the same conditions and the collection tube 
replaced.  Next 500μl of Wash Buffer II was added to the spin column, centrifuged 
for 15 seconds at 12, 000 x g for 15 seconds and the flow-through discarded.  This 
was repeated once.  The membrane was dried by centrifugation for 1 minute at 
room temperature at 12, 000 x g.  The collection tube was replaced with a recovery 
tube and 30μl RNase-free water was placed in the centre of the spin cartridge 
before being centrifuged at 12, 000 x g at room temperature for 2 minutes.  The 
recovery tube then contained the purified total RNA which should be stored at -
80°C unless synthesized immediately. 
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3.5.    cDNA synthesis 
 
The reaction to convert messenger RNA (mRNA) template into complementary DNA 
(cDNA) is catalysed by reverse transcriptase.  The RNA was treated with DNase to 
ensure the removal of all genomic DNA.  The reverse transcriptase enzyme operates 
on a single strand of mRNA, to which oligo dTs bind acting as a primer for the 
reverse transcriptase to bind.  The addition of DNA bases allows the generation of 
complementary DNA based on the pairing of RNA base pairs (A, U, G and C) to their 
DNA complements (T, A, C and G respectively).      
 
cDNA was synthesized from the extracted RNA using the Avian myeloblastosis virus 
(AMV) First Strand cDNA Synthesis Kit (New England BioLabs Inc, Hitchin, Herts, UK) 
was used.  1μl RNA, 2μl d(T)23VN (50μM) and 5μl nuclease-free water were added 
to sterile RNase-free microfuge tubes, denatured for 5 minutes at 70°C.  The tubes 
are briefly microfuged and placed on ice to improve the cDNA yield for long 
messenger RNAs.  10μl of AMV reaction mix and 2μl AMV enzyme mix (or water for 
no enzyme control) is added to each tube.  The cDNA synthesis reaction is then 
incubated at 42°C for one hour before the enzyme is inactivated at 80°C for 5 
minutes.  30μl water is added to each tube to dilute the reaction to 50μl.  The cDNA 
was stored at -20°C in the short term; -80°C for long-term storage.     
 
The cDNA was quantified using NanoDrop ND-1000 spectrophotometer (Thermo 
Fisher) (Table 14).  The 260/280nm absorbance ratio was also given which reflects 
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the RNA purity.    The samples were diluted to an approximate concentration of 
100ng/μl. 
Table 14:  Quantification of RNA and cDNA concentration and quality 
 
Sample RNA  ng/μl RNA A260/A280 cDNA ng/μl cDNA A260/A280 
E2 1 1274.7 2.09 621.6 1.80 
E2 2 1273.5 2.07 836.7 1.84 
E2 3 752.9 2.04 601.3 1.80 
E2 + MPA 1 1055.5 2.06 620.7 1.80 
E2 + MPA 2 1164.2 2.09 563.5 1.81 
E2 + MPA 3 1074.6 2.07 1032.7 1.84 
MPA 1 1262.2 2.08 574.4 1.81 
MPA 2 1416.8 2.12 869.3 1.83 
MPA 3 1254.6 2.08 1140.0 1.86 
FGF 1 908.9 2.01 898.4 1.83 
FGF 2 657.9 2.01 976.6 1.87 
FGF 3 1276.6 2.02 598.0 1.81 
DHT 1 756.2 2.02 807.2 1.83 
DHT 2 920.0 2.03 659.4 1.80 
DHT 3 722.0 2.02 645.5 1.84 
Vehicle 1 638.4 1.99 736.4 1.84 
Vehicle 2 817.7 2.05 583.1 1.79 
Vehicle 3 640.8 1.98 623.6 1.80 
Vehicle 4 1051.7 1.97 786.1 1.82 
Vehicle 5 466.1 1.98 624.2 1.80 
SPCEX123 1447.1 1.87 728.3 1.82 
ESC   1662.0 2.19 
Prostate   716.3 1.79 
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3.6.    RT-PCR 
 
Polymerase chain reaction (PCR) is a technique which amplifies and reproduces 
defined sections of precise genetic material due to thermal cycling.  
 
There are three steps to the PCR reaction: 
1. Denaturing:  cDNA is heated to 95°C to break the hydrogen bonds which 
unite the complementary strands.     
 
2. Annealing:  Primers with complementary sequences to those at either end 
of the region of DNA to be amplified attach (anneal) to their complementary 
sequences.  Too high a temperature could prevent primer binding, and if too 
low the binding would be non-specific.  56°C was used in this project. 
 
3. Extension:  the temperature is lowered to 68°C (as specified by the HotStart 
Taq mix) to allow the Taq DNA polymerase enzyme to work optimally.  The 
enzyme attaches to each primer and incorporates complementary 
nucleotides into the single DNA strand.  This creates a copy of the region 
specified by the primers. 
 
These steps were repeated 30-35 times in this experiment.  With each cycle, each 
single strand of double stranded DNA template was amplified into two separate 
double-stranded DNA.  Once these were separated during denaturing, they became 
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available as a template for the next amplification.  This results in exponential 
amplification of the original DNA template (Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12:  The principles of RT-PCR  
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3.6.1 RT-PCR 
 
A primer mix containing both forward and reverse primers was prepared at a 
concentration of 6.25 μM for each primer pair.  
 
12.5μl  HotStart Taq 2x master mix (New England Biolabs Inc, Hitchin, Herts, 
UK) 
1μl  Primer mix 
10.5μl  Nuclease free water 
  
A master mix stock solution was prepared by adding x times amounts listed above 
and 24μl from this pipetted into UV treated PCR tubes.  1μl of cDNA was added to 
each tube.  Attention was taken to prevent contamination of solution and tubes. 
 
 
The following programme was used for the RT-PCR reaction: 
95°C 30 seconds 
95°C 20 seconds 
56°C 20 seconds  30-35 cycles 
68°C 30 seconds 
68°C 5 minutes 
4°C Hold 
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Primer sequences and product sizes are outlined below (Table 15). 
 
Table 15:  RT-Primers 
 
 
The housekeeping gene YWHAZ was chosen as it has been demonstrated to be a 
stable in the endometrium when analysed using RT-PCR104.  It is therefore a suitable 
and useful housekeeping gene for this experiment. 
 
 
 
 
 
 
Gene Name Sequences Size TM°
C 
PCR product 
size (base 
pair (bp)) 
YWHAZ 
 
Fwd 5’-CGTTACTTCGCTGAGGTTGCC-3’ 21 67.8 69 
Rev 5’-GTATGCTTGTTGTGACTGATCGAC-3’ 24 64.6 
SOX9 Fwd 5’-GTACCCGCACTTGCACAAC-3’ 19 64.3 74 
Rev 5’-TCTCGCTCTCGTTCAGAAGTC-3’ 21 63.8 
SOX2 Fwd 5’-CGAGATAAACATGGCAATCAAAAT-3’ 24 64.6 85 
Rev 5’-AATTCAGCAAGAAGCCTCTCCTT-3’ 23 65.3 
Human ERα Fwd 5’-TGATTGGTCTCGTCTGGCG-3’ 19 67.6 101 
Rev 5’-CATGCCCTCTACACATTTTCCC-3’ 22 66.3 
Human PR Fwd 5’-CAGTGGGCGTTCCAAATGA-3’ 19 67.1 83 
Rev 5’-TGGTGGAATCAACTGTATGTCTTGA-3’ 25 66.3 
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In order to ensure that the PCR reaction had worked, the following positive controls 
were used (Table 16). 
 
Table 16:  Positive controls for RT-PCR 
 
 
 
 
 
 
 
 
 
3.6.2 Agarose gel 
 
In order to visualise the PCR products, electrophoresis was performed using a 1% 
agarose gel with SYBR Safe.  4g of agarose powder (Sigma Aldrich, Poole, UK) and 
40μl SYBR Safe (Invitrogen Ltd., Paisley, United Kingdom) were added to 400ml 1x 
Modified Tris-Acetate EDTA (TAE) buffer (Millipore Corporation, Nottingham, UK) 
and heated in a microwave until completely dissolved.  The solution was then 
poured carefully into a gel tray and air bubbles removed using a pipette tip before 
being left to set.  To prepare the PCR products for electrophoresis, 5μl of loading 
buffer (Type II loading buffer, Abgene, Epsom, UK) was added to each tube and 
mixed well.  When fully cooled, sufficient electrophoresis buffer (1x TAE) was 
poured over the gel to cover both the gel and electrode attachments and the combs 
removed.  5μl of the PCR product solution was added to each well using fresh 
pipette tips for each pipette sample to prevent cross-contamination, 1μl of a 50 bp 
Gene Name Positive control 
YWHAZ SPCEX123 Primary endometrial sample 
SOX9 PC3  Prostate cancer cell line 
SOX2 H7 Embryonic stem cell line 
Human ERα SPCEX123 Primary pre-menopausal endometrial sample 
Human PR SPCEX123 Primary pre-menopausal endometrial sample 
71 
 
DNA molecular weight marker (50bp ladder, New England Biosciences) was placed 
in the first well. 
 
Once the gel had been loaded, the electrodes were connected to the supply unit 
and run at 120 volts for 30-45 minutes, or until the DNA ladder was fully separated.  
The gel was then visualised using the ChemiDoc-It TS2 Imager (UVP systems, 
Cambridge, UK) and photographs taken.  This allows visualisation of the PCR 
products to assess whether there has been any contamination in the negative 
controls, that the products correspond to the correct size, and to quantify the 
products. 
 
3.6.3 Analysis of PCR 
 
Following gel electrophoresis, the PCR bands were analysed using ImageJ software 
(Figure 13).  Each band was isolated, the pixel intensity calculated, and a histogram 
created (x axis = pixel location, y axis = intensity value) using the gel analysis 
function.  The area under the curve represents the amount of signal in the band.  
This was repeated three times for each band and the average calculated. 
 
In order to compensate for intra- and inter-kinetic RT-PCR variations (sample-to-
sample and run-to-run variations) all target gene expression levels were normalised 
to the housekeeping gene YWHAZ.  For each sample, the signal for each test gene 
was divided by the YWHAZ signal for the corresponding sample.  This value was 
used for statistical analysis.   
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3.7. Statistical analysis 
 
Data was analysed using SPSS statistics software (Version 20, IBM) and GraphPad 
Prism software (version 6).  Immunohistochemistry results were compared to the 
normal control (post-menopausal and proliferative) groups.  Global differences 
were assessed using the non-parametric Kruskal-Wallis (KW) test, if this suggested 
that there were differences between the groups, they were investigated using the 
non-parametric Mann Whitney (MW) test.  Correlations between protein 
expression in the primary samples was assessed using the Spearman Rank 
Correlation statistical test (SR).  PCR results were analysed in a similar way using the 
untreated (vehicle) cells as the control.  Statistical significance was set at p <0.05.  
Advice on appropriate statistical tests was gained from Dr Anna Hart (University of 
Lancaster).   
B 
A 
Figure 13:  Quantification of RT-PCR.  A)  Individual bands isolated using 
ImageJ. B)  Histogram of PCR band with area below the curve highlighted. 
B 
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Chapter 4.  Results 
4.1. Patient demographics  
 
This study was performed over a 12 month period from September 2012 – August 
2013.  31 cancer, 10 normal post-menopausal (PM) and 10 normal proliferative 
phase (PP) samples were collected according to the criteria outlined previously and 
analysed using immunohistochemistry (Table 17). 
Table 17:  Patient demographics 
   
The available demographic details of the patients were analysed using Kruskal-
Wallis test and no significant difference was found between any of the study groups 
for BMI (KW p=0.131) or parity (KW p=0.595).  All women with cancer were post-
menopausal, thus as expected, the age of the proliferative group was significantly 
lower than all grades of cancer (KW p = <0.0001) and post-menopausal (KW p = 
<0.0001).  However there was no difference between the grades of cancer and post-
menopausal groups. 
Study Group Sample number  Age BMI Parity Disease stage 
Grade 1  10 Mean (±SD) 
Median 
Range 
63 ± 3 
63 
53 - 83 
38.7 ± 10.5 
39.6 
23.7 – 53.2 
3 ± 2.1 
3 
0 - 5 
1 ± 0.3 
1 
1 - 2 
Grade 2  13 Mean (±SD) 
Median 
Range 
64 ± 10 
60 
51 - 79 
29.5 ± 5.0 
28.9 
21.7 – 37.9 
3 ± 1.7 
3 
0 - 6 
1 ± 0.9 
1 
1 - 3 
Grade 3 8 Mean (±SD) 
Median 
Range 
71 ± 7 
72 
60 - 80 
29.4 ± 6.4 
27.7 
23.9 – 42.7 
2 ± 2.0 
2 
0 - 6 
2 ± 1 
1 
1 - 3 
Post-
menopausal 
10 Mean (±SD) 
Median 
Range 
72 ± 6 
75 
62-78 
28.2 ± 3.4 
27.5 
23.7 – 35.8 
2 ± 0.7 
2 
2 - 4 
 
- 
Proliferative 10 Mean (±SD) 
Median 
Range 
39 ± 5 
39 
30-42 
27.2 ± 7.5 
27.0 
17.5-45.5 
3 ± 1.5 
3 
0 - 5 
 
- 
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 Cancer samples were graded by the pathology department at the Royal Liverpool 
University Hospital (RLUH) and internally verified by a second independent 
pathologist within the department of Women’s Health.  Details of staging were 
obtained from the clinical notes (Figure 18).  No difference was observed between 
the grades of cancer for FIGO stage. 
 
Table 18:  FIGO stage of all cancers 
 
 
 
 
 
 
 
No grade IIIC2 or grade IVB cancers were available for practical reasons; patients 
with metastatic disease are rarely operated on at LWH without prior treatment with 
either radio- or chemotherapy. 
 
 
 
FIGO Stage Sample Number Percentage (%) 
IA 16 57 
IB 5 18 
II 2 7 
IIIA 3 11 
IIIB 1 4 
IIIC1 1 4 
IIIC2 0 0 
IVA 0 0 
IVB 0 0 
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4.2. Results: Immunohistochemistry 
 
51 primary endometrial samples (31 endometrial adenocarcinomas, 10 normal 
proliferative phase and 10 normal post-menopausal) were assessed for the 
expression of 6 proteins (SOX9, Ki67, β-catenin, SOX2, SFRS2 and NAP1L1) using 
immunohistochemistry as previously outlined.  Differential expression between the 
malignant samples and the normal controls was evaluated using the Kruskal-Wallis  
statistical test.  Differences between individual groups were appraised using the 
Mann-Whitney statistical test as previously described.  Correlations between 
protein expression were assessed using the Spearman Rank Correlation test.  
Results were determined to be statistically significant where p<0.05. 
 
4.2.1 β-catenin 
 
 
Wnt/β-catenin signalling is important in the endometrium, maintaining the balance 
between proliferation and differentiation.  Enhanced Wnt/β-catenin signalling is 
implicated in endometrial carcinogenesis.  The transcription factor β-catenin 
enables the transcription of the downstream proliferative genes of the canonical 
Wnt pathway, when it is located in the nucleus and can therefore be used as a 
surrogate for determining Wnt activation105.   
 
There are three possible staining patterns for β-catenin, which reflects its different 
functions; the cell nucleus (A), cytoplasm (B), or adherens cell junction (C) (Figure 
14).  For the purposes of assessing the canonical Wnt/β-catenin pathway, only 
nuclear and cytoplasmic staining was assessed. 
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β-catenin can be seen extensively in both the cytoplasm and nucleus of epithelial 
cells, and therefore two scoring systems were used which quantified these 
separately.  β-catenin was not observed in the stromal compartment.  Overall, 
nuclear staining was differentially expressed between the groups (KW p=0.049); 
grade 1 cancers showed significantly more nuclear staining than PP samples (MW 
p=0.023) (Figure 15).  However, although statistically insignificant at the 95% 
confidence interval, there is a clear trend that nuclear β-catenin is up-regulated in 
cancers in comparison to the non-malignant controls.  13/31 malignant samples 
expressed nuclear β-catenin in comparison to 2/20 benign controls.  Furthermore, 
nuclear β-catenin expression rises with increasing grade of cancer.   
 
Cytoplasmic staining was also differentially expressed across the groups (KW 
p=0.033).  Grade 2 cancers demonstrated lower staining levels than both PP (MW p 
= 0.049) and PM (MW p=0.015) samples.  There would appear to be a similar, but 
opposing trend to nuclear staining, whereby cytoplasmic staining decreases with 
increasing grade.  However, this is far less obvious, and no conclusion could be 
drawn from this.   
 
A 
B 
C 
Figure 14:  Staining patterns of β-catenin.  A) Nuclear B) Cytoplasmic C) Junctional 
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The relationships between β-catenin expression (nuclear and cytoplasmic) and Wnt-
related proteins were investigated using the Spearman’s Rank Correlation test.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
1 
Figure 17: Immunohistochemical staining for β-catenin.  1)  Immunohistochemical staining for β-catenin of normal 
proliferative phase endometrium (n=10), post-menopausal endometrium (n=10)  and endometrial adenocarcinoma 
samples (G1 n=10, G2 n=12, G3 n=8).  A)  200x magnification.  B) 400x magnification.   2) Scatter plots showing 
median, inter-quartile range and range for percentage positively stained nuclei for nuclear β-catenin.  3) Scatter plots 
showing median, inter-quartile range and range for QuickScore of cytoplasmic β-catenin staining.    
  Proliferative       Post-menopausal             Cancer 
β-catenin 
2 3 
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4.2.2 Ki67 
 
Ki67 is seen in the nucleus of proliferating cells in both the stroma and glands of the 
endometrium.  Only staining in the endometrial glands was assessed as this is the 
location of origin of endometrial cancer.  High-grade endometrial cancers also lose 
their stroma, and therefore discounting the stroma of normal tissues provides the 
most appropriate comparison for malignant tissue.  Ki67 staining was up-regulated 
compared to PM controls in all cancer grades (MW p<0.0001) (Figure 16).  PP 
samples also showed increased Ki67 staining compared to PM samples (MW 
p=0.005).  The endometrium becomes atrophic after menopause due to ovarian 
failure; a weak or non-existent proliferative pattern is therefore to be expected.  
With the development of adenocarcinoma, the endometrium regains its 
proliferative potential, therefore increased Ki67 staining.  No statistical difference 
was observed between cancers and PP samples, or between the grades of cancers.   
 
The PP samples demonstrated a wide range of Ki67 staining, with some areas 
having almost every cell positively stained, and other areas with less than 1% 
staining.  On viewing the PP sections at low power, Ki67 was more abundant in the 
functionalis compared to the basalis, although this was not objectively quantified.  
One explanation for the varying Ki67 density could be whether they are early or late 
proliferative phase; this was not possible to assess. 
 
Nuclear β-catenin is associated with transcription of genes associated with 
proliferation.  A higher proliferative index would be expected in regions containing 
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nuclear β-catenin than those without.  Surprisingly, there was no correlation 
between nuclear β-catenin and the proliferation marker Ki67 (data not shown).   
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:  Immunohistochemical staining of Ki67.   
1)  Immunohistochemical staining for Ki67 of normal proliferative phase endometrium (n=10), post-menopausal 
endometrium(n=10)  and endometrial adenocarcinoma samples (G1 n=10, G2 n=12, G3 n=8).  A)  200x magnification 
(scale bar 100μm).  B) 400x magnification (scale bar 50μm) .    
2) Box plots showing median, inter-quartile range and range for estimated percentage positively stained nuclei for Ki67.   
 
    Proliferative        Post-menopausal                    Cancer 
Ki67 1 
2 
a 
b 
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4.2.3 SOX9  
 
SOX9 is known to be associated with the Wnt/β-catenin pathway; SOX9 expression 
has been reported to be dependent on Wnt signalling, but has also been postulated 
to be a regulator of the Wnt/β-catenin pathway.  SOX9 has been postulated to 
attenuate Wnt-target gene transcription, this ensuring Wnt-stimulated proliferation 
is kept in check70, 71. 
 
SOX9 staining was only exhibited in the epithelial and not the stromal compartment 
of the endometrium (Figure 17).  SOX9 was primarily located in the nucleus, 
although cytoplasmic staining was also seen, often in conjunction with nuclear 
staining.  SOX9 is a transcription factor; therefore a nuclear location would be 
necessary to affect transcription of target genes. 
 
Essentially every epithelial cell in PM glands was strongly positively stained for 
SOX9.  Glands in PP samples showed a wider range of staining intensity, but overall 
there was a considerably lower expression of nuclear SOX9 in the PP samples (MW 
p<0.0001) than PM samples.  Malignant samples demonstrated a significant 
decrease (MW p<0.0001) in comparison to PM samples, although there was little 
variation between grades of cancer or between cancer and PP samples.  
Interestingly, where glands have retained normal endometrial glandular 
architecture in the surrounding malignant tissue, SOX9 expression is retained, 
similar to the normal postmenopausal tissue.   It is important to note that for all 
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proteins, but especially SOX9, that the malignant tissue sections comprised of a very 
heterogeneous staining pattern.  
 
Despite its putative relationship with the canonical Wnt/β-catenin pathway, 
expression of nuclear β-catenin and SOX9 were not correlated.  There was however 
a negative correlation between SOX9 and the proliferation marker Ki67 (SR p=0.032, 
correlation co-efficient -0.300).   
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Figure 17:  Immunohistochemical staining of SOX9.  1)  Immunohistochemical staining for SOX9 of normal proliferative 
phase endometrium (n=10), post-menopausal endometrium(n=10)  and endometrial adenocarcinoma samples (G1 
n=10, G2 n=12, G3 n=8).   A)  200x magnification (scale bar 100μm).  B) 400x magnification (scale bar 50μm).   2) Box 
plots showing median, inter-quartile range and range for estimated percentage positively stained nuclei for SOX9.  3) 
Scatter graph to show the correlation between SOX9 and Ki67.    
 
       Proliferative                  Post-menopausal                 Cancer 
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4.2.4 SOX2 
 
SOX2 has been proposed as a marker of progenitor cells due to its roles in 
development, differentiation, pluripotency and the maintenance of a cell’s ability 
for proliferative potential.  SOX2 is also implicated in carcinogenesis in a variety of 
organs, in addition to being proposed as a regulator of the canonical Wnt/β-catenin 
pathway.  The role of SOX2 in the normal and malignant endometrium remains 
unclear.  
 
The expected localisation of SOX2 would be nuclear due to its role as a transcription 
factor, although a significant amount of cytoplasmic staining was also seen.  Whilst 
there was a range of both proportion of positive staining and intensity of the 
cytoplasmic staining between the samples, there was no distinction between 
sample types (KW p=0.283) (Figure 18).  With few exceptions, the proportion of 
positively stained nuclei was <1% across all groups, consequently there were no 
inter-group differences observed (KW p=0.285).  SOX2 defines an undifferentiated 
cell; consequently a low expression would be expected.  However, of the 7/10 
samples which demonstrated >1% nuclear staining and 6/7 samples with >2% 
positive staining were from malignant samples.  All bar one of the samples with >2% 
staining are high grade cancers.  It is possible that the SOX2 expressing cells 
represent a cancer stem cell.  These differences are small, but may suggest that a 
differential expression could be unmasked with a larger sample size.   
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Due to its postulated relationship with the canonical Wnt/β-catenin pathway, a 
correlation was assessed in relation to nuclear B-catenin (SR p = 0.025, correlation 
co-efficient 0.313). 
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Figure 18:  Immunohistochemical staining of SOX2.  1)  Immunohistochemical staining for SOX2 of normal proliferative phase 
endometrium (n=10), post-menopausal endometrium(n=10)  and endometrial adenocarcinoma samples (G1 n=10, G2 n=12, 
G3 n=8).  A)  200x magnification.  B) 400x magnification.    
2) Box plots showing median, inter-quartile range and range for percentage positively stained nuclei for nuclear SOX2.  3) 
Box plots showing median, inter-quartile range and range for QuickScore of cytoplasmic SOX2 staining.  4)  Scatter graph to 
show correlation between SOX2 and nuclear β-catenin.    
 
        Proliferative      Post-menopausal                     Cancer 
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4.2.5 NAP1L1 and SFRS2 
 
The histone chaperone transporter NAP1L1 and splicing factor SFRS2 were 
identified in colorectal carcinoma arrays as being up-regulated downstream of 
nuclear β-catenin in the malignant colon.  NAP1L1 has not been reported previously 
in the endometrium.  SFRS2 has been identified in the normal endometrium in the 
context of implantation.  Neither of these proteins has been investigated in 
endometrial carcinoma. 
 
SFRS2 and NAP1L1 demonstrated positive staining in the endometrial epithelial 
glands, and to a lesser extent the stroma.  Both proteins were expressed in the 
cytoplasm in addition to the nuclei of the cells.  There was no difference in staining 
pattern or intensity between cancer and either the PP or the PM controls (SFRS2:  
KW p=0.124; NAP1L1:  KW p=0.155) (Figures 19 and 20). 
 
Nuclear β-catenin was positively correlated with NAP1L1 (SR p=0.046, correlation 
co-efficient 0.281) and SFRS2 (SR p=0.032, correlation co-efficient 0.301) in line with 
their status as Wnt-related proteins (Figure 21).  NAP1L1 and SFRS2 also 
demonstrated a positive correlation with each other (SR p < 0.0001, correlation co-
efficient 0.613), giving credence to the notion that they share a regulatory pathway.  
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Figure 19:  Immunohistochemical staining of NAP1L1.  1)  Immunohistochemical staining for NAP1L1 of normal 
proliferative phase endometrium (n=10), post-menopausal endometrium(n=10)  and endometrial adenocarcinoma 
samples (G1 n=10, G2 n=12, G3 n=8).  A)  200x magnification (scale bar 100μm).  B) 400x magnification (scale bar 50μm)..    
2) Box plots showing median, inter-quartile range and range for the positive staining index of NAP1L1.   
3) Box plots showing median, inter-quartile range and range for the positive staining index of NAP1L1.    
As previously described, the positive staining index is derived from the ratio of DAB staining (positive) to haemotoxylin 
staining using colour deconcolution and area measurement on ImageJ. 
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Figure 20:  Immunohistochemical staining of SFRS2.  1)  Immunohistochemical staining for SFRS2 of normal proliferative phase 
endometrium (n=10), post-menopausal endometrium (n=10)  and endometrial adenocarcinoma samples (G1 n=10, G2 n=12, G3 
n=8).  A)  200x magnification (scale bar 100μm).  B) 400x magnification (scale bar 50μm)..    
2) Box plots showing median, inter-quartile range and range for the positive staining index of SFRS2.  3) Box plots showing 
median, inter-quartile range and range for the positive staining of SFRS2.    
As previously described, the positive staining index is derived from the ratio of DAB staining (positive) to haemotoxylin staining 
using colour deconcolution and area measurement on ImageJ. 
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Figure 21:  Correlations between nuclear β-catenin and the Wnt-related proteins NAP1L1 and SFRS2.   
A) Scatter plot to show relationship between nuclear β-catenin and NAP1L1.  B)  Scatter plot to show 
relationship between nuclear β-catenin and SFRS2.  C)  Scatter plot to show relationship between 
NAP1L1 and SFRS2. 
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4.3. PCR 
 
Oestrogen and progesterone are key regulators of the human endometrium, both in 
the healthy and disease state.  Their potent effects on proliferation are mediated 
through their steroid receptors.  In malignancy, the balance of these interactions is 
disrupted and can result in clinical implications.  For example, progesterone is a 
well-tolerated, potent anti-proliferative agent, but its clinical use is limited in 
endometrial cancer as it is difficult to predict sensitivity15.  SOX9 is another 
postulated regulator of cell proliferation through the canonical Wnt/β-catenin 
pathway.  IHC demonstrated a very high SOX9 expression in the atrophic 
endometrial epithelial glands, with a significantly lower expression in the 
proliferative tissues.   
 
In order to investigate the effects of ovarian hormones on endometrial cancer, a cell 
line (well differentiated Ishikawa cell line derived from a grade 1 endometrial 
adenocarcinoma) was employed. The chosen treatments represent the dominant 
hormones involved in endometrial regulation.  Oestrogen (E2) was used both alone 
and in combination with progesterone (a synthetic, highly potent progestagen 
MPA106).  Progesterone (MPA) was also assessed in isolation from oestrogen.  Since 
some of the effects of progestagens in the endometrial epithelial cells are thought 
to be mediated via FGF15 (basic FGF), this was also assessed.  The dominant 
hormones in the post-menopausal endometrium (the primary location for 
endometrial carcinogenesis) are androgens (potent AR agonist DHT), despite this, 
they have not been widely investigated7.   
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The mRNA of expression of expression of oestrogen receptor α (ERα), progesterone 
receptor (PR) and SOX9 were assessed using RT-PCR and compared to untreated 
cells (vehicle).   
 
The PCR products are shown below after electrophoresis and image capture (Figure 
22).  mRNA expression of each gene was quantified by densitometry on ImageJ, and 
normalised to the housekeeping gene YWHAZ.  The Kruskal-Wallis test was 
performed to show differences between the treatments for each gene.  Where 
differences were demonstrated, the Mann-Whitney test was performed to 
investigate where the differences lie.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22:  Gel electrophoresis of PCR products 
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4.3.1 Oestrogen receptor α 
 
No difference was noticed between treatments in expression of ERα. (Figure 23, 
Table 19). 
 
Table 19:  Densitometry results for Oestrogen receptor α 
 
 
 
 
 
 
Treatment Densitometry Normalised 
Ratio 
Mean 
normalised 
Ratio 
1 2 3 Average 
E2 16833.87 16495.04 16601.45 16643.45 0.86 
0.69 
 
E2 8618.75 10049.53 10507.77 9725.35 0.46 
E2 15446.5 17004.4 15984.74 16145.21 0.76 
E2 + MPA 13561.26 13524.26 13983.09 13689.54 0.66 
0.75 
 
E2 + MPA 16625.28 16625.28 17742.64 16997.73 0.78 
E2 + MPA 14212.43 16037.71 16741.54 15663.89 0.82 
MPA 18648.99 18438.99 18126.16 18404.71 0.87 
0.88 
 
MPA 17531.45 18505.94 18055.11 18030.83 0.85 
MPA 18810.57 19251.81 19748.64 19270.34 0.94 
FGF 14942.62 15758.28 16031.11 15577.34 1.07 
0.94 
 
FGF 14877.92 15896.28 17159.35 15977.85 0.83 
FGF 19834.67 20983.16 21087.16 20635 0.94 
DHT 20677.97 22380.11 21468.45 21508.84 1.09 
0.93 
 
DHT 18092.26 18924.21 19360.74 18792.4 0.89 
DHT 17437.69 18606.76 18033.94 18026.13 0.82 
Vehicle 19372.38 20891.28 20278.04 20180.57 0.92 
 
Vehicle 14655.72 16265.28 15966.87 15629.29 0.74 
Vehicle 17830.16 17838.4 18386.23 18018.26 0.86 
Vehicle 20490.21 20647.62 21085.87 20741.23 0.98 
Vehicle 15800.67 17787.11 17992.11 17193.3 0.88 
Figure 23: RT-PCR for oestrogen receptor α.  Box 
plots showing normalised ratios of densitometry 
values for mRNA levels of ERα following 72-hour 
ovarian steroid hormone treatment. 
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4.3.2 Progesterone receptor 
 
Progesterone receptor was up-regulated by E2, E2+MPA and DHT from the baseline 
(vehicle).  Neither MPA nor FGF altered the expression of SOX9 (Figure 24, Table 
20). 
Table 20:  Densitometry results for Progesterone Receptor 
Treatment Densitometry Normalised 
Ratio 
Mean 
normalised 
Ratio 
1 2 3 Average 
E2 17730.57 19170.06 19751.3 18883.98 0.97 
0.96 
 
E2 18612.47 19493.42 20424.08 19509.99 0.91 
E2 20550.76 21735.25 21631.84 21305.95 1.00 
E2 + MPA 15500.87 17101.42 17458.84 16687.04 0.80 
0.78 
 
E2 + MPA 17456.35 18324.59 19098.25 18293.06 0.84 
E2 + MPA 13112.04 12975.45 14530.84 13539.44 0.71 
MPA 8657.6 9293.26 9387.84 9112.9 0.43 
0.51 
 
MPA 10205.24 10813.48 11953.79 10990.84 0.52 
MPA 11557.97 11788.38 11999.38 11781.91 0.57 
FGF 7973.7 8399.7 8978.94 8450.78 0.58 
0.55 
 
FGF 6143.32 6510.97 6887.22 6513.837 0.34 
FGF 15696.94 16563.59 16236.18 16165.57 0.73 
DHT 20443.54 22325.27 20688.96 21152.59 1.07 
1.02 
 
DHT 24063.2 25745.34 24741.27 24849.94 1.18 
DHT 17122.94 17899.84 18839.91 17954.23 0.81 
Vehicle 7733.92 7759.51 8313.75 7935.727 0.36 
 
Vehicle 6263.44 7793.87 7621.87 7226.393 0.34 
Vehicle 11958.64 12984.84 12201.64 12381.71 0.59 
Vehicle 16609.42 16615.42 16721.42 16648.75 0.79 
Vehicle 10492.92 10757.33 11861.52 11037.26 0.56 
 
 
 
Figure 19:  RT-PCR for progesterone receptor.  
Box plots showing normalised ratios of 
densitometry values for mRNA levels of PR 
following 72-hour ovarian steroid hormone 
treatment. 
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4.3.3 SOX9 
 
SOX9 was down-regulated by MPA, FGF and DHT in the region of 1.5-fold.  Neither 
E2 nor E2+MPA treatment altered the expression of SOX9 (Figure 25, Table 21).  
Table 21:  Densitometry results for SOX9 
Treatment Densitometry Normalised 
Ratio 
Mean 
normalised 
Ratio 
1 2 3 Average 
E2 11026.82 9762.05 10285.87 11026.82 0.53  
0.45 
 
E2 9229.75 8284.1 8855.22 9229.75 0.41 
E2 8980.41 8377.75 8435.46 8980.41 0.41 
E2 + MPA 8904.87 8869.87 9069.29 8904.87 0.43  
0.41 
 
E2 + MPA 8832.22 8594.8 8438.39 8832.22 0.40 
E2 + MPA 7507.97 7647.39 7762.39 7507.97 0.40 
MPA 5612.37 6083.61 5939.2 5612.37 0.28  
0.30 
 
MPA 6823.02 6531.9 6890.73 6823.02 0.32 
MPA 6614.73 6289.9 6484.73 6614.73 0.32 
FGF 4524.3 4891.54 4383.3 4524.3 0.32  
0.31 
 
FGF 6297.07 5941.25 5946.25 6297.07 0.31 
FGF 7011.27 6707.44 6985.56 7011.27 0.31 
DHT 5454.37 5216.42 5341.12 5454.37 0.27  
0.30 
 
DHT 5804.95 5284.71 5959.37 5804.95 0.27 
DHT 8171.95 7884.54 8545.2 8171.95 0.37 
Vehicle 7851.15 7469.61 7907.44 7851.15 0.35 
 
Vehicle 11229.2 12611.39 13373.63 11229.2 0.59 
Vehicle 9252.85 8853.32 9419.85 9252.85 0.44 
Vehicle 9109.44 9249.27 9258.85 9109.44 0.44 
Vehicle 9719.8 9711.8 9557.1 9719.8 0.49 
 
Figure 20: RT- PCR for SOX9.  Box plots 
showing normalised ratios of densitometry 
values for mRNA levels of SOX9 following 
72-hour ovarian steroid hormone 
treatment. 
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Chapter 5. Discussion 
 
 
The canonical Wnt/β-catenin pathway plays a vital role both in the functioning of 
the normal endometrium, and in endometrial carcinogenesis.  Traditionally, the 
endometrium has been viewed as being dominated by progesterone and oestrogen 
– both of which can modulate the Wnt/β-catenin pathway.  However, endometrial 
adenocarcinoma is almost exclusively a disease of the post-menopausal 
endometrium which is by definition hypo-oestrogenic.  Investigation of other Wnt-
pathway modulators in the endometrium is therefore crucial to further our 
understanding of this common malignancy.  SOX9 has been previously described to 
limit Wnt/β-catenin induced proliferation69, has well described interactions with the 
prostatic androgen receptors107, and has been shown here to be highly expressed in 
the androgen mediated atrophic post-menopausal endometrium.  The results 
presented here provide further evidence for the pivotal role played by Wnt in the 
endometrium, as well as preliminary data on a role for SOX9 and androgens.   
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5.1. Expression of Wnt-related proteins in primary endometrial 
samples 
 
Immunohistochemical analysis of the relative expression of the Wnt-related 
proteins β-catenin, SOX9, SOX2, NAP1L1 and SFRS2, and the proliferation marker 
Ki67 was performed in endometrial adenocarcinoma, normal proliferative phase 
and post-menopausal samples.  The Wnt/β-catenin pathway is known to have an 
important role in the normal endometrium as it maintains the balance between 
stemness and proliferation108.  Aberrations of this pathway are frequently seen3.  
APC is one of the most common mutations in endometrial cancer109; without APC 
the destruction complex cannot function and enables the Wnt-related proteins to 
be expressed beyond the control of Wnt.  The Wnt-related proteins examined here 
have all been described in other related cancers, but little is known in the 
endometrium.  The potential implications of the findings for each of the proteins 
are discussed below. 
 
5.1.1 β-catenin 
 
The canonical Wnt/β-catenin pathway is known to have an important role in 
regulating normal endometrial homeostasis.  During the normal menstrual cycle, 
high oestrogen levels induce Wnt activation during the proliferative phase.  This is 
counterbalanced by progesterone during the secretory phase which inhibits Wnt/β-
catenin signalling, therefore inducing differentiation3.  Dysregulation of this 
pathway caused either by hormonal imbalance or mutations are implicated in 
endometrial carcinogenesis109. 
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Immunohistochemical staining of β-catenin reveals a varied pattern of expression in 
the endometrium, with junctional, cytoplasmic and nuclear accumulation being 
seen (see Figure 14).  As previously discussed, this represents the functional roles of 
β-catenin, and it is therefore important to consider the intra-cellular compartment 
in which it lies in order to assess Wnt activation.  Transcription of the down-stream 
proliferative genes, within the benign setting, is dependent on nuclear β-catenin 
acting as a transcription factor.   
 
5.1.1.1. Nuclear β-catenin expression in the benign endometrium  
 
The benign endometrium demonstrated primarily cytoplasmic and junctional 
staining, with nuclear β-catenin seen very rarely in the proliferative functionalis.  
The literature suggests that nuclear β-catenin expression is up-regulated in the 
proliferative phase105 of the normal endometrium, which was not seen here.  
However, these studies rarely differentiate between the functionalis and basalis 
layers.  Where the functionalis and basalis have been regarded separately, the 
results are similar to that found here32, 50, 110.  It has recently been reported that 
nuclear β-catenin is a feature of the basalis layer12, which in addition to mediating 
the regeneration of the functional layer is the proposed location of origin of the 
endometrial proliferative conditions12.   
 
The basalis of the pre-menopausal endometrium is reported to have a similar gene 
signature to the post-menopausal endometrium32; it is perhaps therefore to be 
expected that the post-menopausal group displayed increased nuclear β-catenin 
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compared to the proliferative functionalis.  Moreover, the post-menopausal 
endometrium has been demonstrated to have intact Wnt/β-catenin signalling, 
although under a negative feedback loop in order to down-regulate transcription of 
the proliferative genes75.  The basalis layer of the pre-menopausal samples was not 
assessed in this study, as the primary aim was to provide a suitable control for 
endometrial cancer samples which were all pipelle rather than full-thickness 
samples, and not to characterise the normal endometrium.  The limitations of this 
will be discussed.   
 
5.1.1.2. Cytoplasmic β-catenin expression 
 
The role of cytoplasmic β-catenin is more difficult to distinguish.  Activation of the 
canonical Wnt/β-catenin pathway, results in translocation of β-catenin to the 
nucleus and subsequent transcription of downstream proliferative genes111.  
Conversely a lack of Wnt activation should result in β-catenin degradation by the 
destruction complex.  It has been proposed that increased cytosolic levels of β-
catenin encourage translocation to the nucleus, and therefore some degree of 
cytoplasmic β-catenin is necessary for Wnt-related proliferation112.  On the other 
hand, β-catenin has three potential binding partners, only one of which (TCF/LEF) 
lies in the nucleus; both the cadherins and Axin/APC are cytoplasmic in origin112.  It 
has been suggested that on leaving the ribosome, the first binding partner is 
cadherin.  Only when there is surplus β-catenin than is required for the adherens 
junctions does it become available to Axin/APC.  If Wnt activation occurs, β-catenin 
can translocate to the nucleus and bind to the third binding partner TCF/LEF, 
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otherwise, it is degraded by the second112.  Whilst not formally assessed, junctional 
β-catenin (bound to cadherin at the adherens junctions), could be seen in the 
absence of either cytoplasmic or nuclear β-catenin.   
 
5.1.1.3. β-catenin expression in endometrial adenocarcinomas 
 
Nuclear β-catenin was present in approximately 40% of the endometrial 
adenocarcinoma samples.  The range in estimates of Wnt/β-catenin pathway 
activation as measured by nuclear β-catenin staining is very large, from 16-85%89, 
113.  The number of Wnt-activated samples studies here sits squarely in the middle 
of these estimates.  In the same manner that there is no consensus on the incidence 
of samples expressing nuclear β-catenin, any association between grade of cancer 
and expression is equally unclear.  This study found that there was no significant 
difference of nuclear β-catenin expression between the grades of cancer, which has 
been previously been reported105, 114.  It must be noted that the samples sizes used 
here are small, which decreases the likelihood of inter-group differences being 
significant.  There was also no difference in nuclear β-catenin expression between 
the cancer samples and normal controls.  This is somewhat surprising since β-
catenin mutations are an early step in endometrial tumorigenesis, and may also be 
involved in later disease progression65.  However, when presented graphically 
(Figure 16) the data shows a clear trend for higher expression in malignant samples.  
It appears that nuclear β-catenin may be associated with stage rather than grade; 
low-stage cancers appear to express more nuclear β-catenin than invasive 
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disease115.  This was not possible to assess due to not having access to high-stage 
disease samples. 
 
This study found that cytoplasmic β-catenin was only differentially expressed 
between both of the normal controls and grade 2 cancers.  However, there would 
appear to be a trend in decreased cytoplasmic staining and increasing grade of 
cancer; the reverse of the trend for nuclear β-catenin.  It could be inferred from this 
that the cytoplasmic pool of β-catenin is being depleted due to nuclear 
translocation.  However, due to the uncertainty of the implications of cytoplasmic 
β-catenin outlined above, the utility of assessing cytoplasmic β-catenin is 
questionable.  This is perhaps best demonstrated by the correlation of nuclear β-
catenin and the Wnt-related proteins SOX2, SFRS2 and NAP1L1, none of which were 
directly correlated with cytoplasmic β-catenin. 
 
 
5.1.1.4. Association between nuclear β-catenin expression and proliferation 
 
The lack of correlation between Ki67 and nuclear β-catenin is perhaps surprising; 
however, this lack of association has previously been described97, 116.  There has 
been a report of a correlation between Ki67 and nuclear β-catenin117, although this 
study included endometrial adenocarcinoma patients who had received 
progesterone treatment.  There is a distinct lack of literature which directly analyse 
the relationship between nuclear β-catenin accumulation and a marker of 
proliferation such as Ki67 in the endometrium.  It is unlikely that the mechanism 
which regulated the complex nature of proliferation and regeneration in the 
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endometrium is a simple one, and it is likely that several mechanisms interact.  
Moreover, in the malignant state there is a high occurrence of aberrations in the 
Wnt/β-catenin pathway, and Wnt activation in the absence of nuclear β-catenin has 
been reported in other cancers112.  Another point to consider would be that 
malignancies are heteregenous in nature, and nuclear β-catenin staining was not 
evenly distributed across entire sections.  It was not always possible to use 
consecutive sections from the tissue-containing paraffin blocks, which may affect 
the correlations between proteins. 
 
5.1.2 Ki67 
 
The Wnt/β-catenin pathway regulates the fine balance between proliferation and 
differentiation in the endometrium; nuclear β-catenin has been used as a marker of 
Wnt-activation105.  Wnt activation is associated with transcription of down-stream 
genes such as NAP1L1 and SFRS2.  In order to assess whether Wnt-related protein 
expression was associated with proliferation, Ki67 was used. 
 
The post-menopausal endometrium, increasingly recognised as not always being 
entirely quiescent, shows low-levels of proliferation7.  This was demonstrated by 
the Ki67 scores, which were representative of a far lower proliferative index than 
either the PP or cancer samples.  Without exception, the post-menopausal samples 
displayed low Ki67 staining, although whilst some glands appeared to be entirely 
quiescent, others showed some low-level proliferative activity.  These could 
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represent the proliferative foci in the active post-menopausal endometrium due to 
low level oestrogenic activity described by Sivridis et al.33. 
 
That post-menopausal endometria are not all entirely inactive has long been 
known118, 119, however, the extent of activity and the risks that this may pose are 
becoming increasingly known.  As previously discussed, Sivridis et al.33 propose that 
endometrial adenocarcinomas are derived from the glands which demonstrate 
some proliferative activity in response to low level oestrogenic stimulation in the 
presence of a functioning ER system.  They conclude that the risk of developing 
endometrial adenocarcinoma from inactive glands is exceptionally low.   
 
The proliferative index of the cancer samples was equal to, if not lower than the PP 
samples.  It could be proposed that the high-grade cancers ought to show 
significant levels of proliferation, which they do when compared to the quiescent 
PM tissue.  There are several factors to consider when interpreting this result.  
Firstly, the normal endometrium possesses a remarkable ability to regrow the entire 
functionalis layer in a matter of a few days, and so it is entirely plausible that the 
proliferative phase glands express more Ki67 than their malignant counterparts.  
Secondly, whilst Ki67 expression is strictly correlated with active phases of the cell 
cycle and cell proliferation, and is one of the most widely accepted markers, it is 
representative only of a snapshot in time.  Ki67 staining will be negative when cells 
are not in the active cell cycle, and therefore cannot predict proliferative potential.  
In order to do this a marker such as proliferating cell nuclear antigen (PCNA) would 
have to be used.  PCNA was not included in the staining panel, as its role is not 
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confined to DNA replication, but is also involved in DNA repair.  Additionally, the 
sections were analysed by scoring ten consecutive high-power fields, which ought 
to balance the considerable heterogeneity shown by the cancer samples.  However, 
it is possible that it has not accounted for this entirely. 
 
The normal proliferative phase samples showed a considerable range in staining. 
This could be related to the inter-mitotic period, but it is more likely that there is an 
intra-phasic variation in proliferation during the phase.  For the purposes of this 
study, proliferative phase endometrium was diagnosed on the basis of histological 
dating and last menstrual period, and no differentiation was made between early 
and late phase.  It would not be unexpected for levels of proliferation to vary during 
this period in response to hormone levels, and it is known that later in the phase 
the glands show increased levels of proliferation10.  It may be of utility to sub-divide 
the PP samples into an early and late proliferative phase group by integrating the 
peripheral hormone profile into the dating of the sample.  It must also be noted 
that discrepancies occur between different dating methods, and it is not possible to 
control for all variables such as length of menstrual cycle. 
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5.1.3 SOX9 
 
High expression of SOX9 was identified by the post-menopausal endometrium97, 
and it was speculated that it may have a role in maintaining the atrophic state.  
SOX9 has been shown to be up-regulated or down-regulated in many cancers, 
thereby suggesting a tissue specific role68.  
 
The nuclear expression of SOX9 was investigated, although it was noted that where 
nuclear staining was positive, cytoplasmic staining was invariably also present.  One 
of the postulated functions of SOX9 is that it is a transcription factor; therefore 
nuclear location would be in keeping with its expected function.   
 
SOX9 was solely expressed in the endometrial glandular epithelium, and not in the 
stromal compartment.  The endometrial progenitor cells are thought to reside in 
the basalis layer, which is the proposed location of origin of cancer initiating cells, 
and therefore endometrial adenocarcinoma12.  The basalis layer persists beyond 
menopause, therefore retaining the putative progenitor cells in the post-
menopausal endometrium12.  Virtually all post-menopausal epithelial cells were 
strongly SOX9 positive.  Both of the highly proliferative endometrial tissues (PP and 
cancer samples) demonstrated a significant reduction in SOX9 staining.  Moreover, 
SOX9 was negatively associated with Ki67 expression.  This may suggest that SOX9 
has a role as a marker of low proliferative activity in the endometrium.   
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To date, there has only been one published report of SOX9 in the malignant 
endometrium67.  The results presented by Saegusa et al., show conflicting 
relationships proliferative index and SOX9.  Their immunohistochemistry results 
demonstrated a positive relationship with Ki67, which was contradictory both to the 
proliferative profiles shown in their transfection studies, and to the results 
presented here.  Stable over-expression of SOX9 in the HEC251 endometrial cancer 
cell line by transfection resulted in a decrease in cell proliferation. 
 
There are several key differences between the data presented by Saegusa et al. and 
that described here.  Firstly, the study group consisted of 55 endometrioid 
endometrial carcinomas, of which only 23 were post-menopausal women.  Due to 
the considerably different conditions between the normal cycling endometrium and 
the atrophic post-menopausal endometrium, the mechanisms of carcinogenesis are 
likely to be different106.  This selection of samples is therefore unlikely to be a 
representative population, since 93% of cases are diagnosed in women aged over 
50115.  One of the key limitations of this paper is the use of proliferative phase 
endometrium as the positive control.  As previously discussed, the vast majority of 
endometrial adenocarcinomas arise from the post-menopausal endometrium; 
therefore it would be inappropriate to form a conclusion on the relative up- or 
down-regulation of a protein without first considering the post-menopausal 
endometrium.  In fact Saegusa et al. report a significant up-regulation in 
endometrial hyperplasia; this may point to loss of SOX9 during carcinogenesis, since 
hyperplasia is an intermediary between the normal post-menopausal endometrium 
and malignancy. 
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The types of biopsy used, and the methods of analysis are slightly ambiguous.  
Firstly the authors do not state whether the benign samples were pipelle or full-
thickness samples, or comment on whether the basalis and functionalis layers were 
considered separately.  It is very difficult to determine what is classified as ‘normal’ 
in the human endometrium, due to the wide variation in menstrual cycles and 
symptoms, and the use of drugs which affect physiology and morphology; no details 
of exclusion criteria were given.   
 
In addition to this there were also potential methodological differences between 
the studies.  Saegusa et al.. stated that the stroma did not express SOX9, but it is 
unclear whether or not stromal cells were included in the labelling indices, as the 
references given for the methodology do not include benign samples.  The results 
appear to show that 10% of PP cells are SOX9 positive; the images appear to show 
considerably more positive epithelial cells than this.  The PP samples stained 
showed considerable variation in staining (Figure ), since both studies used a sample 
size of 10, it is possible that this accounts for the difference.  On the other hand, as 
Saegusa et al. used microwave antigen-retrieval, it is possible that the sections 
show a falsely low expression.   
 
The differences displayed between these studies highlight the need for further 
investigation of SOX9 in the normal and malignant endometrium.   
 
The prostate is an androgen influenced malignancy, which also has a well described 
relationship with SOX9.  Wang et al.107 have demonstrated that SOX9 contributes to 
107 
 
both decreased cellular proliferation and regulation of the androgen receptor to 
which it can specifically bind.  SOX9 can modulate both expression and activity of 
prostatic AR.  SOX9 expressing basal epithelial cells are thought to support the 
development and maintenance of the prostatic luminal epithelium, and a subset of 
prostate cancer cells may escape basal cell requirements through SOX9 expression.  
Huang et al., have furthered this by suggesting that by maintaining a prostate 
epithelial lineage which is responsive to oncogenic stimuli, SOX9 permits the 
initiation of prostate carcinogenesis120.   
 
The role of SOX9 in maintaining stem/progenitor cells in other tissues such as the 
intestine, liver, pancreas and hair follicles has been implicated in the pathogenesis 
of several cancers121,122. 
 
An activated Wnt pathway has been demonstrated in the post-menopausal 
endometrium32, however, this tissue remains relatively quiescent.  SOX9 loss in the 
intestine causes both hyperplasia and dysplasia in the glandular epithelium70.  In 
addition there was up-regulation of Wnt target genes.  It would not biologically 
implausible to propose that SOX9 is one of the mechanisms by which Wnt-induced 
signalling was inhibited in the post-menopausal endometrium.  Loss of SOX9 may 
release this anti-proliferative effect resulting in carcinogenesis.   
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5.1.4 SOX2 
 
SOX2 has previously been investigated in the normal, endometriotic and malignant 
endometrium due to its numerous postulated roles.  It has long been accepted as a 
marker of embryonic stem cells, but has also been associated with the canonical 
Wnt/β-catenin pathway and implicated in carcinogenesis102.     
 
 
Nuclear SOX2 was expressed at a low-level across all the study groups.    For the 
vast majority of samples, both benign and malignant, expression was <1% of all 
epithelial cells.  There would appear to be a (non-statistically significant) increase in 
the grade 3 carcinoma group.  Of the 10 samples which expressed >1% positive 
cells, 7 of these were malignant samples.  The proportion of malignant cells with 
even higher expression (>2%) was 6/7 samples.  Expression of SOX2 represents a 
stem-like cell, therefore it is to be expected that few cells were SOX2+; the SOX2+ 
malignant cells may be representative of a cancer stem cell.   
 
The reports of SOX2 in the endometrium are very contradictory.  The range of 
reported expression spans from sparse distribution in both benign100 and malignant 
endometrium99, 123.  Some reports suggest that SOX2 expression is in accordance 
with the stem-like cell markers OCT4 and NANOG123, while other reports that its 
expression is 60 times lower95.  SOX2 has also been reported to be absent in the 
human endometrium101.  The low level of nuclear expression reported here, is 
therefore in accordance with the current literature base.  SOX2 has been reported 
to be essential to maintaining proliferative potential, and together with NANOG 
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forms part of the transcriptional regulatory circuitry for pluripotency and self-
renewal.  However, the actions of SOX2 are not autonomous, and must bind to 
other factors such as OCT4 in order to regulate transcription93.  
 
It was not possible to pre-power the sample sizes, due to the minimal published 
data on endometrial SOX2 expression.  Therefore increasing numbers of samples 
may unmask an underlying differential expression.  The relevance of cytoplasmic 
SOX2 remains unclear.  There was significant variation in both area and intensity of 
cytoplasmic staining, although this appeared to be independent of the sample 
group.  In the Wnt/β-catenin pathway setting, SOX2 acts as a transcription factor, so 
it is likely that the nuclear expression of SOX2 is the most relevant. The differential 
expression of cytoplasmic SOX2 may be related to another function of the protein.  
It is also possible that the cytoplasmic staining here is due to a lack of antibody 
specificity, possibly due to splice variants, as is the case in OCT4124.      
 
The SOX family of transcription factors have increasingly been identified as key 
regulators of β-catenin/TCF activity in a variety of biological contexts69.  SOX2 is a 
member of this family, and has therefore been investigated as a regulator of the 
canonical Wnt/β-catenin pathway.  Closely related to TCF proteins, SOX proteins can 
act as either activators or repressors of Wnt signalling69.  One common feature of 
the Wnt pathway are negative feedback loops111, of which SOX2 appears to be one. 
In addition to stimulating β-catenin activity SOX2 has been reported to be directly 
regulated by Wnt69.  In concordance with this hypothesis, nuclear SOX2 was 
correlated with nuclear β-catenin.  Although this would appear to confirm its status 
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as a Wnt-related protein, there must be some caution, as this correlation is reliant 
on one sample in this data set.  Further investigation with a larger sample size is 
therefore necessary.  It is also beyond the scope of this study to establish whether 
SOX2 is an up-stream regulator of Wnt in addition to being a target gene.   
 
The role of SOX2 in malignancy is not fully understood, and it seems to act in a 
tissue-specific manner.  For example, SOX2 expression in breast cancer is associated 
with aggressive properties due to induction of β-catenin induced proliferation69, 125.  
Conversely, SOX2 is often down-regulated in gastric cancer, but when present 
represses proliferation92.  In the endometrium, hypermethylation of SOX2 has been 
reported to be linked to histological subtype, being more common in Type II 
endometrial carcinomas (non-endometrioid)96.  SOX2 methylation also appears to 
be contradictory as a prognostic marker; it has been reported to both be associated 
with a shorter survival, and with expression of PR (more commonly considered to 
be a marker of good prognosis)96.  On the other hand, SOX2 mRNA has been 
observed to be greater in endometrial tumorosphere cells than differentiated 
cells99.  Given the paucity of corresponding results between study groups, further 
investigation is required before consensus on a role for SOX2 in the endometrium 
can be reached. 
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5.1.5 NAP1L1 and SFRS2 
 
 
Unpublished data (Jenkins et al.) reports that NAP1L1 and SFRS2 are up-regulated 
downstream of β-catenin in colorectal carcinoma.  Both proteins are inducible via 
APC knock-out, and show differential expression between malignant polyps and 
adjacent normal tissue in both the mouse and human colon.  SFRS2 has also been 
reported in the mouse, primate and human endometrium using 
immunohistochemistry, RT-PCR and Northern blotting 84, 91, 126.  There have not 
been any previous reports of NAP1L1 in the endometrium. 
 
The staining patterns of SFRS2 and NAP1L1 appear to be similar to that already 
reported in both the colon and endometrium.  Neither SFRS2 nor NAP1L1 displayed 
any inter-group variation in expression by analysis using colour deconvolution and 
area measurement.  Subjectively, it had appeared that malignant samples typically 
had a higher intensity of staining.  Colour deconvolution is a very useful analysis tool 
as it is entirely objective, but it is limited in its ability to differentiate between 
staining intensities.  Whether a difference in staining intensity could be of use when 
both proteins express some degree of cytoplasmic staining ubiquitously is hard to 
define.  One potential method for bypassing this problem would be to quantify 
NAP1L1 and SFRS2 expression using PCR.  In retrospect, a QuickScore may have 
been a more appropriate scoring method. 
 
SFRS2 and NAP1L1 were both correlated to nuclear β-catenin expression, as well as 
being correlated to each other.  The first correlation appears to support the 
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hypothesis that they are down-stream proliferative proteins of the Wnt/β-catenin 
pathway.  The second may suggest that they are both regulated by the same means 
i.e. by Wnt/β-catenin pathway.   
 
The vital role that the Wnt/β-catenin pathway plays in the maintenance of the 
normal endometrium, outlined previously, is well documented.  It could therefore 
be expected that these two down-stream proteins would be expressed in all the 
study groups.  The expression of nuclear β-catenin was not statistically different 
between the groups (other than PP and grade 1 cancers).   The expression of these 
Wnt-regulated proteins could reasonably be expected to mirror that of β-catenin.  
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5.2. The effect of hormonal treatment on the transcription of SOX9, 
Oestrogen Receptor α and Progesterone Receptor. 
 
The immunohistochemical analysis of primary endometrial samples demonstrated 
that SOX9 is down-regulated in endometrial adenocarcinoma compared to normal 
post-menopausal controls at the protein level.  In order to perform a functional 
analysis of SOX9, a well-differentiated endometrial adenocarcinoma cell line 
(Ishikawa) were grown in phenol red-free media with charcoal stripped serum, prior 
to treatment with ovarian steroid hormones for 72hrs.     
 
The treatments were chosen due to their known importance in the normal or 
malignant endometrium.  Oestrogen (E2) is well established as the single most 
important risk factor for developing endometrial cancer, as well as being 
instrumental in its maintenance30.  Progesterone on the other hand has important 
anti-proliferative effects and is used as an adjuvant therapy in treating high grade or 
stage disease15.  The effects of progestagens are mediated by FGFs released by the 
stroma15.  Since the Ishikawa cell line represents a mono-cellular system, and lacks 
the stromal signalling pathways FGF was used as a separate treatment to account 
for this.  Androgens are the most abundant circulating steroid hormone in the post-
menopausal endometrium6.  Local and circulating androgen production has been 
linked to endometrial hyperplasia and malignancy; significantly elevated 
testosterone levels have been found in endometrial carcinomas34.  It has even been 
postulated that there is a possible direct role for androgens in endometrial 
carcinogenesis45, 127. 
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5.2.1 Oestrogen receptor α 
 
The proliferative effects of endogenous oestrogens are mediated by the oestrogen 
receptors ERα and ERβ, although in endometrial carcinogenesis ERα is thought to be 
the primary mediator18.  Reduction in levels of ERα in endometrial adenocarcinomas 
are related to increased epithelial-mesenchymal transition and poorer prognosis128.  
Hormone receptor status and response to therapy has been widely discussed128, 129; 
it appears that personalised therapy based on steroid receptor status may provide a 
solution to what is currently not a particularly effective therapeutic option130. 
Furthermore, the development of an adjuvant therapy which is capable of 
inducing/suppressing steroid receptors as appropriate could significantly improve 
the outlook for patients dependent on non-surgical treatment. 
 
The expression of ERα was not altered by any of the treatments in this experiment.  
This is not entirely consistent with the literature which suggests that Ishikawa cells 
retain their ability to auto-regulate their hormone receptors in response to E2.  
There are several possible explanations for this.  The response of ERα to oestrogen 
is the most widely investigated of the hormone treatments, and although most 
studies have been able to show ERα up-regulation in response to oestrogen 
exposure, the response shown appears to be duration dependent.  It is likely that 
ERα has a fast response to oestrogen exposure; up-regulation has been described as 
early as 7 hours post-treatment (although studies at 3 hours showed no effect131).  
It is therefore possible that by assessing ERα status at 72 hours, the effect has 
passed.  Johnson et al.132 demonstrated that whilst ERα expression increased during 
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their 24h culture, the effect was not further increased by oestrogen treatment.  
Given the lack of consensus in the literature, a further investigation to assess 
expression at multiple time-points would be beneficial.  This time-point was 
appropriate for the other proteins (PR and SOX9).   
 
Progesterone treatment (MPA and FGF) could also have been expected to down-
regulate ERα.  One explanation for non-responsiveness to treatment is that the 
different populations of Ishikawa cells have gained different mutations which affect 
their ability to respond to treatment.  Characterisation of the Ishikawa cell line using 
immunofluoresence in our laboratory (results not presented), show high levels of 
both ERα and Ki67 staining.  This may suggest that ERα is already expressed at its 
highest level, so it is not possible for expression to be increased.  If this activation is 
genetic mutation driven, it would therefore be unlikely that hormonal treatments 
would alter this activation.  The effect of DHT treatment on the normal or malignant 
endometrium has not been established, therefore it is possible that DHT may not 
alter ERα expression.  
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5.2.2 Progesterone receptor 
 
In the normal cycling endometrium, progesterone exerts anti-proliferative effects 
via the steroid hormone receptor PR and FGF signalling.  Attempts to exploit this 
mechanism in endometrial adenocarcinomas so far have not been particularly 
successful.  Progesterone treatment is used in a palliative setting; however, a recent 
Cochrane review casts doubt on its efficacy130.  This is partly due to difficulties in 
predicting hormone sensitivity, although recent investigations suggest the use of 
stromal may emerge as a reliable biomarker48.  One future challenge is to re-
sensitise hormone refractory cancers to hormonal therapies. 
 
In contrast to ERα, PR responded to the ovarian hormone treatments in the 
Ishikawa cells.  PR was up-regulated by oestrogen treatment, which is in keeping 
with the literature133.  When MPA was added to oestrogen to provide a 
combination treatment, the overall effect was again an increase in PR expression, 
although to a lesser degree than to oestrogen alone.  On the other hand, 
progesterone did not have any effect on the expression of its own receptor.  This 
would suggest that when given in combination, oestrogen provides the dominant 
influence on the Ishikawa cells.  It has been demonstrated in endometrial 
carcinoma, that regardless of epithelial PR status, progesterone will only have an 
effect if stromal PR are present and functional15.  In the normal endometrium, 
progesterone relies on FGFs being released by the stromal cells in order to regulate 
endometrial cells.  The Ishikawa cell line lacks any stromal cells, which may explain 
why it does not respond to MPA.  However, in order to compensate for this we also 
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treated with FGFs which did not have an effect on PR levels either.  FGF receptor 
status was not characterised prior to treatment, so it is possible that the Ishikawa 
cells lack the appropriate receptor in order for PR to respond to treatment.  On the 
other hand, the resistance of progesterone receptor to regulation by MPA may be 
due to an aberration in hormonal control which is a key feature of endometrial 
carcinogenesis.   
 
DHT which has not been widely investigated in the context of the endometrium was 
also noted to up-regulate PR, which has not previously been reported in Ishikawa 
cells.  Androgen treatments can be administered systemically, and may prove to be 
a promising area of future research as an adjuvant therapy.   
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5.2.3 SOX9 
 
SOX9 was found to be up-regulated in the atrophic endometrium of the PM samples 
when compared to the highly proliferative PP and adenocarcinoma samples.  
Interactions between SOX9 and the ovarian steroid hormones are not understood in 
the endometrium, although array data points to oestrogen-induced SOX9 down-
regulation75.  One key similarity between the PP and cancer samples other than the 
decreased SOX9 expression is the dominance of oestrogen.  However, the 
treatment of the Ishikawa cells with E2 did not have an effect.  In fact, the combined 
treatment of E2+MPA produced a slight decrease in SOX9 transcript, suggesting that 
in a similar fashion to the expression of PR, oestrogen is the dominant factor in the 
combination. 
 
The expression of SOX9 transcript was down-regulated by DHT; androgen induced 
modulation of SOX9 expression could be expected considering their well described 
interactions107, 121.  On the other hand, both the progesterone related compounds 
MPA and FGF also down-regulated SOX9.  There have not been any previous 
functional studies assessing the response of SOX9 transcript or proteins levels to 
hormonal treatment in the endometrium published.  However, if as postulated, 
SOX9 in normal benign cells reduces proliferation, it would be expected that MPA 
would up-regulate SOX9 since it is a potent anti-proliferative agent in the 
endometrium.  The Ishikawa cell line is well-differentiated, so it could be expected 
that normal regulation is preserved.  However, that was not what was seen here.  In 
endometrial adenocarcinoma, the canonical Wnt/β-catenin pathway is known to be 
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often dysregulated.  It is therefore possible that the mechanism by which SOX9 
interacts with pathways such as Wnt is disrupted in malignancy.  It could even be 
suggested that dysregulation of the pathway as seen in normal cells may cause 
paradoxical up-regulation in cancer cells; SOX9 has been reported as both an 
inhibitor and promoter of proliferation. 
 
The in vitro model used here may also be a limitation.  For example, if the protein 
level is increased, but has a long half-like, by 72 hours, the mRNA may not be 
increased.  In order to assess this, Western blotting would be required.  The cell 
culture method here was 2D, and although the Ishikawa cell line is well 
characterised, it is possible that it does not respond in the same way that primary 
cancers do in vitro. 
 
The results presented here are only a preliminary investigation into the effects of 
ovarian steroid hormones on SOX9.  Further studies are required into the functional 
roles, interactions and regulation of SOX9. 
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5.3. Limitations  
 
The results of the immunohistochemical characterisation were limited by multiple 
factors.  Primarily the sample sizes which were chosen for feasibility of collection 
and analysis during the one year project may mask differential expression of the 
Wnt-related proteins.  In addition, as this was novel research, it was not possible to 
determine a clinically useful difference and therefore pre-power the sample sizes.  
Moreover, the quantification methods required the use of non-parametric 
statistical tests which reduces the strength of the evidence, and are more likely to 
produce a non-significant p-value. 
 
Determining an appropriate control for comparison to the malignant samples was 
not entirely straightforward; consequently neither of the controls used (PP and PM 
normal endometrium) provide a perfect comparison.  The appropriate control could 
be considered to be endometrial tissue which is under the influence of oestrogen, 
which in turn is the primary known regulator in endometrial cancer development 
and maintenance, such as proliferative phase samples.  On the other hand, the vast 
majority of Type 1 endometrial cancers, including all of the malignant samples used 
in this study occur in post-menopausal women.  However, post-menopausal 
samples lack proliferative potential.  To further complicate matters, only pipelle 
samples were available for the malignant samples.  For this reason only the 
functionalis layer of the proliferative phase samples was assessed as the basalis is 
not collected by a pipelle.  However, the post-menopausal endometrium is most 
similar to the pre-menopausal basalis layer which was not assessed.  It may be 
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expected that the malignant samples retain features of the post-menopausal 
endometrium, and therefore the basalis.  Despite this, it would not be appropriate 
to discard the proliferative samples as otherwise changes seen in the normal 
proliferative endometrium could be mistaken for malignant variations.  For these 
reasons, both proliferative phase and post-menopausal samples were used as 
controls.  The Wnt down-stream proteins, although not formally assessed, did not 
appear to have a significant difference in expression between the two layers.  On 
the other hand, both the β-catenin and SOX9 expression is reported to vary 
significantly between the layers12.  It may have been appropriate to use laser 
capture to isolate benign tissue within the sample as the normal control.  However, 
this has the disadvantage that whilst it may appear morphologically normal, the 
cells may have biochemical and genetic derangements which cannot be seen 
macroscopically and therefore are not truly ‘normal’ either.  Whilst every effort was 
taken to ensure that an appropriate normal control was used, these factors must be 
considered when interpreting the results.   
 
No stage IIIb or IV cancer samples were available for analysis.  Samples were 
collected from patients undergoing hysterectomy, however, those diagnosed with 
metastatic disease are usually initially treated with chemo- or radiotherapy.  
Samples collected from this patients would not be suitable, as these treatments 
alter the morphology and functioning of the tumours. 
 
Only one housekeeping gene (YWHAZ) was used to normalise the expression of the 
target genes in the PCR experiments.  Whilst it has been reported to be the 
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housekeeping gene of choice for the endometrium104, the results would be more 
robust if two genes were used.  Moreover there were three biological repeats of the 
hormone treatment experiment, but technical repeats of the RT-PCR would improve 
the strength of the data.  Furthermore the use of quantitative RT-PCR would 
increase the accuracy of the reading and provide a quantitative rather than a semi-
quantitative output.  In addition, as previously discussed, in order to fully assess the 
expression of ERα it may be appropriate to repeat the experiment to create a time-
response curve. 
 
In order to fully assess the effect or non-effect of the steroid hormones, it would be 
necessary to fully characterise the receptor status of the Ishikawa cell line.    
Moreover there are further complications to consider when assessing the effect of 
the treatments.  For example, MPA is capable of binding to PR, AR as well as the 
glucocorticoid receptor, whilst having only a weak affinity of ER.  In order to fully 
block the effects of oestrogen, a specific oestrogen blocker would be required 
rather than relying on competitive blocking by MPA.  There were also limitations 
with the PR primer used as it could not discriminate between the two PR subtypes 
(PRa and PRb) which are both expressed by Ishikawa cells, therefore could only give 
a global picture of total PR levels.  Furthermore, the results presented here only 
represent the Ishikawa cell line’s response to these specific conditions.  The 
functional analysis of SOX9 would therefore benefit from the use of multiple cell 
lines, 3D rather than 2D cell culture and an increased range of both treatment 
concentrations and combinations of hormones.  Furthermore it would be beneficial 
123 
 
to investigate the effects of treatments at the protein levels using Western blots in 
addition to the mRNA level. 
 
5.4. Further work 
 
Numerous questions arise from the data presented here, primarily regarding the 
functional assessment of SOX9.  The number and combination of hormonal 
treatments as well as means of quantification were limited by the timescale of this 
project.  Since DHT appeared to diminish the expression of SOX9, it may be 
beneficial to perform a dose-response curve to establish whether a higher 
concentration may have an even greater effect.  This is a particularly interesting 
avenue of investigation as androgens are the dominant hormone in the post-
menopausal endometrium, and it is in this phase that SOX9 expression dramatically 
increases.  It would not be biologically implausible for androgens to mediate this 
change, and may allow the therapeutic exploitation of the anti- proliferative effects 
of SOX9. 
 
 
The other treatments which reduced SOX9 expression were both MPA and FGF, it 
would equally be interesting to investigate whether either of these would act as an 
adjuvant with DHT.  Another combination treatment to consider would be using E2 
and DHT together. 
 
124 
 
In order to ensure the feasibility of this project, only one cell line was assessed.  
However, it may be beneficial to extend this study and to use endometrial cancer 
cell lines which possess different characteristics such as grade, invasion and 
metastatic potential and hormone receptor status.  For example Hec1a and MFE280 
which are less well differentiated and demonstrate a greater invasive ability could 
be used.  Another possibility to expand this investigation would be to use xenografts 
from primary endometrial adenocarcinoma samples. 
 
SOX9 expression in the primary samples was negatively correlated with the 
proliferation marker Ki67.  It is highly expressed in the largely quiescent post-
menopausal tissue, but is down-regulated in both the highly proliferative tissues 
studied.  Whether SOX9 is the causative feature of low-proliferation, or a down-
stream protein in an anti-proliferative pathway is yet to be ascertained.  A logical 
next step to assess the functional role of SOX9 in vitro would be to switch on/off 
SOX9 and evaluate the subsequent effect on proliferation, expression of Wnt-
related proteins and invasiveness as demonstrated in explant cultures.  
Furthermore the effect on SOX9 if cells were treated with chemotherapeutic agents 
could be assessed.  In view of the regulatory effect that SOX9 appears to have on 
the androgen receptor in the prostate, this would be an intriguing line of enquiry in 
the endometrium. 
 
SOX9 has also been investigated as a prognostic marker in other cancers including 
breast cancer134.  It would be possible to collect both survival and outcome data for 
the samples which have been characterised for their SOX9 expression here, which 
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could provide an interesting extension of possible SOX9 functions.  Furthermore, 
endometrial cancer has an acknowledged pre-malignant stage.  It would therefore 
be of benefit to assess SOX9 status in primary hyperplasia samples. 
 
5.5. Clinical relevance 
 
The Wnt/β-catenin pathway is acknowledged to be crucial in endometrial 
carcinogenesis, and these findings would appear to support this.  However, the 
Wnt/β-catenin pathway is also vital for normal homeostasis of the endometrium, 
and therefore could not be directly therapeutically targeted.  In consideration of the 
poor clinical outcomes for advanced disease, which have shown little improvement 
in recent years, the lack of effective non-surgical therapeutic options, and the trend 
of increasing incidence, novel therapies need to be established.   
 
It is being increasingly accepted that not all post-menopausal endometria are equal 
when it comes to the risk of endometrial carcinoma, and that there is a higher risk 
group of women with active endometrial glands, about which we know little.  
Moreover, the only hormones to have been properly considered in the context of 
endometrial regulation are oestrogen and progesterone.  Endometrial cancer is not 
a disease of the cycling endometrium, there is a need to investigate the dominant 
hormone in the post-menopausal state – androgens.  Expanding knowledge in this 
area is vital for furthering our understanding of endometrial carcinogenesis.  In 
addition, given the lack of efficacy of the hormonal treatment currently used, this 
may open a way for a novel treatment for endometrial cancer. 
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High-dose progesterone treatment is frequently used in the management of 
advanced disease, but it is limited both by the loss of progesterone receptor and 
the dysregulation of the progestagen signalling pathways.  Whilst it would not be 
appropriate to use oestrogen to up-regulate PR, DHT also increased the levels of PR 
transcript in the Ishikawa cell line and could be considered for further investigation 
as an adjuvant to MPA treatment. 
 
The expression pattern of SOX9 also lends itself to investigation as a potential 
diagnostic marker in post-menopausal women.  Characterisation of the hyperplastic 
endometrium would be required.  Similarly, if SOX9 does have an inhibitory effect 
on proliferation, it may be possible to exploit this in the management of 
endometrial cancer. 
 
5.6. Conclusions  
 
The canonical Wnt/β-catenin pathway has a crucial role in regulating the normal 
endometrium, as well as the transition to malignancy.  The transcription factor β-
catenin was not significantly increased in malignancy, although there is a trend for 
increasing Wnt-activation in high-grade disease.   
 
The results here represent the first identification of the Wnt-related proteins 
NAP1L1 and SFRS2 in the malignant endometrium, and NAP1L1 in the benign 
endometrium.  The expression of NAP1L1, SFRS2 and SOX2 was not different in the 
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malignant compared to the benign endometrium.  However, expression was 
correlated to that of nuclear β-catenin, thus providing further evidence of their 
status as Wnt-related proteins. 
 
SOX9 expression in the atrophic post-menopausal endometrium was up-regulated 
compared to that of the highly proliferative malignant and proliferative phase 
endometrium.  The proliferation marker Ki67 was also negatively associated with 
SOX9 expression, suggesting an anti-proliferative role.  SOX9 expression appeared 
to be independent of Wnt activation. 
 
The expression of SOX9 in the Ishikawa endometrial adenocarcinoma cell line can 
be manipulated by the ovarian sex steroid hormones; treatment with MPA and DHT 
results in down-regulation.  The role of oestrogen and progesterone in regulating 
the normal cycling endometrium has long been established and has been 
extensively explored.  However, the role of the other ovarian sex steroid hormone, 
androgen, has been rarely investigated.  The cell culture experiments performed 
here provide preliminary data on a role for androgens in regulating the 
endometrium. 
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Appendix 3:  Positive and negative controls for immunohistochemistry 
 
Figure:  Controls for immunohistochemistry. Negative control, external positive control and internal 
positive control.  All pictures were taken at 400x magnification. 
